STEM CELLS by Parry, David Michael & Al Sowaimel, Lujain F.
Worcester Polytechnic Institute
Digital WPI
Interactive Qualifying Projects (All Years) Interactive Qualifying Projects
August 2008
STEM CELLS
David Michael Parry
Worcester Polytechnic Institute
Lujain F. Al Sowaimel
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/iqp-all
This Unrestricted is brought to you for free and open access by the Interactive Qualifying Projects at Digital WPI. It has been accepted for inclusion in
Interactive Qualifying Projects (All Years) by an authorized administrator of Digital WPI. For more information, please contact digitalwpi@wpi.edu.
Repository Citation
Parry, D. M., & Al Sowaimel, L. F. (2008). STEM CELLS. Retrieved from https://digitalcommons.wpi.edu/iqp-all/2177
IQP-43-DSA-2639 
IQP-43-DSA-4172 
 
 
 
 
STEM CELLS 
 
 
 
 
An Interactive Qualifying Project Report 
 
Submitted to the Faculty of 
 
WORCESTER POLYTECHNIC INSTITUTE 
 
In partial fulfillment of the requirements for the 
 
Degree of Bachelor of Science 
 
By: 
 
 
 
____________________          ____________________ 
                                      Lujain Al Sowaimel                        David Parry 
 
 
 
August 27, 2008 
 
 
 
 
 
 
 
APPROVED: 
 
 
_________________________ 
Prof. David S. Adams, Ph.D. 
Project Advisor 
 2
ABSTRACT 
 
 
  
 The use of stem cells is a relatively new technological advancement in medicine, and is a 
heavily debated topic world-wide.  The purpose of this project was to investigate this topic, 
especially key debated points to make recommendations and opinions. The findings and 
discussions of this project are based on a variety of sources, and help clarify some common 
misperceptions. 
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PROJECT OBJECTIVES 
 
 
The purpose of this project is to investigate the topic of stem cells, focusing especially on 
key debated points.  Sufficient background was obtained to allow the authors to make general 
recommendations and opinions. 
 
 
Chapter 1- STEM CELL TYPES AND SOURCES 
  
 Chapter 1 is an overview of what stem cells are and discusses the different types of stem 
cells that are used in medical research and applications.  It also explains how each type of these 
cells is obtained.  The outcome of this chapter allows the reader to understand that not all stem 
cells are alike, each has its own properties and ethical issues. 
 
 
Chapter 2- STEM CELL APPLICATIONS 
  
 In this chapter, specific examples of stem cell applications are described.  Some of the 
applications are treatments that have been proven safe and effective while others are in the 
development stage and are still being researched in animal models or in early human trials.  
Chapter 2 demonstrates the potential uses for these stem cells, as a beginning point for 
subsequent ethical discussions. 
 
 
Chapter 3- STEM CELL ETHICS 
  
 Chapter 3 explains the moral issues that are involved with using various types of stem 
cells.  There is a wide spectrum of positions taken on the use of stem cells, and this chapter 
summarizes different opinions from religious groups, to political views concerning different 
types of stem cells and their uses. 
 
 
Chapter 4- STEM CELL LEGALITIES 
 
 Chapter 4 discusses the legal issues that regulate the use of stems cells for medical 
treatments and research.  Similar to chapter 3, there are many different opinions on stem cells 
and therefore many different federal and state laws have been passed on the use of stem cells, 
including laws that support the use of the cells through funding, or laws that completely prohibit 
the use of specific types of stem cells.   
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CHAPTER-1:  STEM CELL TYPES AND SOURCES 
 
What Are Stem Cells?  
 Stem cells are often termed the “master” cells of the body because they are unspecialized 
cells with the ability to renew themselves for many years through cellular division. They can 
differentiate into different types of cells with specialized functions if proper conditions are 
available; in particular, factors that control cell structure and function can produce these 
conditions that lead to differentiation (National Institute of Health, 2005).  One type of “master 
cell,” the human embryonic stem cell (hESC), possesses unique properties including a normal 
karyotype, high telomerase activity, and long-term proliferation, a process which provides for 
unlimited growth. These cells can amazingly differentiate into the three embryonic germ layers if 
they are transferred to an in vivo environment (Odorico et al., 2001).  Stem cell division is 
asymmetric (Figure-1), producing either daughter cells of the same biological potential, or 
producing cells of lesser more specialized potential. 
 
 
 
 
 
 
Figure 1: Asymmetric Stem Cell Division.  Totipotent cells (upper center) such as a 
newly fertilized egg, have the greatest biological potential.  Pluripotent stem cells 
(center) such as ES cells, have excellent but slightly lesser potential.  Multipotent 
stem cells (lower left) such as hematopoietic stem cells, are able to differentiate into 
several related cell types.  Unipotent stem cells (lower right) can usually only 
differentiate into one type of tissue (Why Files Guide to Stem Cells, 2008). 
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When people think about stem cells, many tend to think only of destroyed embryos.  And it 
is this notion that embryos are destroyed that makes many in the public uncomfortable.  And this 
discomfort has led to a lot of controversy.  When some people hear the expression “stem cells,” 
they think of destroyed fertilized human eggs which are, in their minds anyway, tiny, little 
humans.  However, adult stem cells (ASCs), and in particular hematopoietic stem cells (HSCs) 
isolated from bone marrow, have been used for more than 40 years for people who underwent 
bone marrow transplantation.  And these cells raise far fewer ethical debates. This means that not 
all stem cells are the same, which many people do not realize.   In fact, stem cells can be obtained 
from sources other than embryos, including some adult organs, fetal tissues, umbilical cords, and 
placentas (Godandscience, 2004).  Recently, scientists have discovered that even cells isolated 
from a baby’s tooth or amniotic fluids may have the possibility of forming different cell types 
(Frequently Asked Questions on Stem Cell Research, 2006).  In this chapter, stem cells types and 
sources are explored in more detail. Some sources and types are less controversial than (ESCs) 
because no embryo destruction is involved, yet such cells still have some potential to cure 
debilitating diseases.  
Stem Cells Potencies     
Not all stem cells have the same potency to give rise to all body cells (Figure-2). Totipotent 
stem cells (diagram upper part) are represented by the fertilized egg, the zygote.  These types of 
cells can differentiate into any type of cells, including the three germ layers (ectoderm, 
mesoderm, and endoderm) and the placenta (Adult Stem Cells, 2006).  Pluripotent stem cells 
(purple in the figure) are less specialized than totipotent stem cells, where they only give rise to 
the cells derived from the three germ layers.  Pluripotent stem cells are derived from the inner cell 
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mass (ICM) of a blastocyst (Adult Stem Cells, 2006) and are represented by embryonic stem (ES) 
cells. Multipotent stem cells (diagram right center) are limited to differentiating into specific 
types of cells, and they are found in adult tissues (MedIndia.com, 2006). Examples of multipotent 
stem cells are hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs).  Unipotent 
stem cells are usually capable of forming only one type of cell (National Institute of Health, 
2005).  An example of a unipotent stem cell is neuronal stem cells (NSCs) (diagram lower 
center).   Some stem cells are more powerful than others, but future research may help equalize 
their potentials, allowing the use of less controversial types for a variety of medical applications.   
 
 
 
 
 
 
 
 
 
 
Figure 2: Origin, Isolation, and 
Specialization of Stem Cells.  This 
diagram shows various types of stem cells.  
Those with the greatest biological potencies 
(i.e. able to differentiate into the largest 
number of different tissues) are shown at 
the top.  Potency decreases with lower 
positions on the diagram.  (Chaudry, 2004). 
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Embryonic Stem (ES) Cells  
Scientists have been able to obtain ESCs from mice as long as 20 years ago (National 
Institute of Health, 2005).  ESCs are derived from a 5 to 6 old-day embryos (Embryonic Germ 
Cells, 2007). This type of stem cell has the potential to virtually become any cell type, except for 
placenta. After ovum fertilization by a sperm, a zygote is formed and embryonic development 
begins (National Academy Press, 2001). The zygote divides, then after 3 to 4 days, the embryo is 
composed of 12 or more cells known as a morula (National Academy Press, 2001). After 5 to 6 
days, the embryo is termed a blastocyst, a hollow sphere 150 microns in diameter (National 
Academy Press, 2001). Blastocysts form an outer layer called the trophoblast, and an inner layer 
composed of a cluster of cells called the inner cell mass (ICM).  By this time, 70 cells constitute 
the trophoblast layer, while 30 cells make up the inner cell mass or ES cells (National Academy 
Press, 2001). 
Isolating and Culturing ESCs  
Human embryonic stem cells are isolated through the removal of the ICM into a plastic 
laboratory culture dish containing a nutrient broth known as a culture medium (National Institute 
of Health, 2005). Then the cells start to divide and coat the surface of the dish. Usually, the inner 
surface of the dish is also covered with mouse embryonic skin cells which are designed so they 
will not be able to divide (National Institute of Health, 2005).  This layer is called the feeder 
layer, which provides a sticky surface where ESCs can attach (National Institute of Health, 2005). 
The purpose of using the feeder layer is to supply the medium with the essential nutrients and 
growth factors.  
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Efforts are being made to develop new ways to maintain ESCs without using a mouse 
feeder layer (National Institute of Health, 2005) to avoid exposing the ES cells to animal proteins 
that might affect the transplant compatibility of the ES cells.  The medium includes bovine serum. 
However, adding a cytokine, leukemia inhibitory factor (LIF), to the bovine serum containing 
medium permits the mouse ES cells to proliferate without using a feeder layer (Thomson, 2006). 
To prevent stem cell differentiation and specialization, scientists are studying internal and 
external cell signals (National Institute of Health, 2005) that help maintain an undifferentiated 
state.  Internal signals are controlled by a cell’s genes, while external signals are chemicals 
produced via physical contact with nearby cells (National Institute of Health, 2005).  
Since 1998, around 200 embryonic stem cell lines have at some point been in use 
nationally (Blow, 2008). However, ethical issues concerning ESCs led the US government to 
allow federal money to support only cell lines established prior to August 2001 (discussed in 
Chapter-4), and to establish a list of 21 embryonic stem lines which can be utilized for research 
goals (Blow, 2008). Since then, huge efforts were put forth to improve techniques for stem cells 
culturing.  
Induced Pluripotent Stem Cells (iPS) 
In June 2006, Shinya Yamanka, of Kyoto University in Japan, created a method in which 
stem cells can be produced without cloning or destroying embryos (Holden and Vogel, 2008). 
Yamanka’s idea was based on reprogramming adult mouse fibroblast cells to ESCs, instead of 
eggs. Four genes - Oct3/4, Sox2, c-Myc, and Klf4 (Cyranoski, 2008) -which encode transcription 
factors, were transferred into the fibroblast cells using retroviruses (Cyranoski, 2007). These 
factors stimulate the expression of other genes which make cells convert into pluripotent stem 
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cells with the ability to produce any type of cells in the human body (Cyranoski, 2007) except 
placenta.  
After Yamanka produced iPS cells in mice, researchers were able to create iPS cells in 
humans. They found that four-transcription factors, known as Oct4, Sox2, Nanog, and Lin28, 
were able to reprogram human fibroblast to ESCs. The iPS cells were found to possess normal 
karyotypes, express telomerase activity, and to display other traits characteristic of hESCs.  These 
human iPS lines were shown to be useful for research purposes (Yu et al., 2007) yet do not have 
the strong ethical concerns of ES cells. 
 
Embryonic Stem Cell Sources  
a. In vitro fertilization  
Currently, there are about 400,000 fertilized human embryos in frozen storage in the United 
States that are used to treat infertile couples, but roughly 2.8% are predetermined to be discarded 
(Thomson, 2006 ). In vitro fertilization (IVF) clinics are considered to be a big reservoir of ESCs. 
Fertilization normally occurs in a woman’s body, but in some cases when a woman has 
difficulties conceiving, IVF is a solution (The National Academy of Science, 2008).  IVF requires 
a surgeon to take a woman’s egg through an operation.  In this surgery, the doctor uses hormones 
to stimulate a woman’s ovary to produce several mature eggs. Doctors usually fertilize all the 
donated eggs to maximize the probability that one egg will produce a viable blastocyst that can be 
re-embedded in a woman’s womb. Since not all the attempted fertilized eggs are implanted again, 
any excess of blastocyts are kept in freezers serving as a bank for ESCs (The National Academy 
of Science, 2008).  
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Excess blastocysts obtained via IVF and not used for reproduction are sometimes used for 
medical research purposes, with the donor’s consent.  However, IVF embryos not created for 
reproductive purposes have raised some ethical concerns since these purposely made blastocyts 
would be made knowing they would never develop into a human being (The National Academy 
of Science, 2008).  In order for researchers to use frozen embryos, they have to obtain consent of 
the couple who originally donated the fertilized eggs for reproductive purposes (The National 
Academy of Science, 2008). One disadvantage of ES cells derived from IVF embryos is that such 
cells will be genetically rejected without the continual application of immunosuppressive drugs in 
the host since they are not genetically engineered to match a patient; rejection occurs when the 
recipient’s body recognizes these cells as a foreign body (Byrne et al., 2007).                                 
       
b. Somatic Cell Nuclear Transfer  
Somatic cell nuclear transfer (SCNT) is another method for obtaining ESCs. This technique 
involves placing a nucleus from an already differentiated somatic adult cell, such as a skin 
fibroblast cell, into a donated egg that is free of its nucleus (Frequently Asked Questions on Stem 
Cell Research, 2006). In this case, the egg will contain the genetic material that is specific to the 
host the nucleus was obtained from. Then the egg is cultured to form a blastocyst from which 
ESCs are derived (Figure-3). The nuclear DNA is the same as the host so the ES cell graft would 
not be rejected (The National Academy of Science, 2008).  However this SCNT process has only 
successfully been done in mice and primates, not in humans yet. 
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          In addition to providing patient-specific ES cells, preparing ES cell lines from patients 
with specific genetic diseases would create ES lines in which to study the process by which a 
particular disease develops.  As is the case for IVF, SCNT requires the egg donor’s consent.  
And as with any ES cell preparation process involving blastocysts, SCNT has ethical issues 
because it involves the destruction of a blastocyst (The National Academy of Science, 2008).  
But what is to come may eventually nullify any arguments against these present ethical concerns. 
Once SCNT has been achieved for humans, in the future, scientists can possibly create 
“personalized” stem cells containing the DNA from a specific patient (The National Academy of 
Science, 2008). A big advantage of this technique, as opposed to stem cells obtained from non-
enucleated eggs, is that the patient’s body will not reject the stem cell transplants. Since stem 
cells generated via SCNT are purposely genetically engineered to match that patient, this it is 
referred to as therapeutic cloning (The National Academy of Science, 2008), or oocyte-assisted 
reprogramming (Baker, 2007). Therapeutic cloning differs from reproductive cloning (i.e. Dolly 
the world’s first cloned mammal), in which a cloned embryo is implanted into a womb and 
allowed to develop into a complete individual (The National Academy of Science, 2008).  
Figure-3:  Obtaining ES Cells Through 
Somatic Cell Nuclear Transfer.  This 
process involves taking a nucleus from an 
adult somatic cell (upper right) and injecting 
it into an enucleated egg (diagram center).  
The egg is then cultured to make a 
blastocyst (lower center) from which ES 
cells are obtained that are genetically 
identical to the donor of the adult nucleus.  
(The National Academy of Science, 2008).  
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Therapeutic cloning aims to use stem cells to help individuals stricken with devastating diseases 
which have no cure or effective therapies otherwise. 
Nature reported the accomplishment of producing ES cell lines by SCNT using the nuclei 
from adult rhesus monkey cells (Baker, 2007), and scientists are now trying to achieve the same 
in humans. A team led by Shoukhart Mitalipov at the Oregon Health & Science University in 
Portland successfully obtained primate ES cell lines using the method of SCNT.  The team took 
nuclei from skin cells of an adult monkey and inserted those into an enucleated egg from fertile 
monkeys. After blastocyst formation, the cells in the ICM were taken and cultured on laboratory 
dishes forming embryonic stem lines (Baker, 2007).   A South Korean group reported the first 
derivation of human ESC line (SCNT-hES-1) using the technique of SCNT (Yu and Thomson, 
2006) however this report was subsequently retracted due to fraud, so to date no reliable report 
exists for SCNT success in humans.  
 
c. Parthenotes 
  The process of parthenogenesis, known since the 1900s (Henahan, 2002), is defined as a 
process by which a single egg can develop in the absence of a male counterpart (Brevini and 
Gandolfi, 2008). This mechanism of reproduction is found in some animals including ants, bees, 
flies, lizards, and snakes, which can reproduce without the contribution of a male’s genetic 
material. Mammalian oocytes can undergo artificial parthenogenesis in vitro by mimicking the 
calcium wave induced by a sperm at usual fertilization (Brevini and Gandolfi, 2008).  
Parthenogenetic stimulation can be accomplished at different stages along occyte meiosis, 
which result in parthenotes with different chromosome complementation (Brevini and Gandolfi, 
2008).  Since both parental genomes are needed for generating a functional mammalian genome 
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parthenogenetic blastocysts lack a functional genome. Usually parthenotes cannot develop 
further than a few cell divisions (Brevini and Gandolfi, 2008).  
A team led by Dr. Daley obtained ESCs through the process of parthenogenesis in mice 
(Macintyre, 2007). Another group composed of Yan-Ling Feng and Jerry Hall of the Institute for 
Reproductive Medicine and Genetics in Los Angeles was able to show that it could obtain stem 
cells, which would later have the ability to develop into neurons from mouse parthenotes 
(Holden, 2002). David Wininger, a fertility specialist from Maryland, was able to grow human 
pES (parthenogenetic ES) cells to the blastocyst stage (Westphal, 2003), however the stem cells 
taken were alive only for a few days. Mammalian parthenotes usually die before implantation in 
the womb, but they can survive long enough to be sources of ES cells.  
One disadvantage to obtaining stem cells by parthenogenesis is that this process cannot be 
used to make genetically compatible ES cells for men, or for women after menopause. On the 
other hand, cells made via parthenogenesis have two identical sets of chromosomes; therefore, 
they have less variation in the surface proteins on the cells that can stimulate an immune 
response (Westphal, 2003). 
 
d. Single-Cell Biopsy 
        The discovery of a new way to obtain ESCs through single cell removal from an embryo 
without any destruction has rooted hope for stem cell research with fewer ethical concerns 
(Gearhart and Moreno, 2006). Generating ESCs using single-cell biopsy is similar to the one 
used in preimplantation genetic diagnosis that does not hinder embryonic development 
(Klimanskayza et al., 2006), thus an embryo can potentially serve as a source of ES cells while 
still retaining complete competence for reproduction. 
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Germ Embryonic Stem Cells 
Germ embryonic stem cells (GECs), also known as embryonic germ cells (EGCs), are 
derived from a part of the embryo known as the “gonadal ridge”. Usually, these germ cells have 
the ability develop into eggs or sperm.  Such cells are isolated from fetuses older than 8 weeks of 
development.  As opposed to ESCs, GECs do not form tumors upon transferring to the body, 
thus making them a reliable source for transplant tissue and cell-based therapies. However, 
EGCs raise some ethical challenges for researchers because they are derived from embryos older 
than blastocysts or from aborted fetuses (Embryonic Germ Cells, 2007). 
 
Adult Stem Cells (ASCs)  
          ASCs help to maintain homeostasis by renewing or replacing the dead or injured cells in 
an adult organism. Some scientists describe ASCs as somatic stem cells whose origin is not 
defined (Adult Stem Cells, 2006).  They have less differentiation potential than ES cells, but they 
can usually be differentiated to obtain the major specialized cell type of the tissue or organ in 
which they reside (National Institute of Health, 2005).  ASCs are found most often in the organs 
that need a continuous supply of cells and that are undergoing constant cell division, such as the 
blood, the skin, the lining of the gut, and the brain (although the brain is not widely known to 
renew its cells) (The National Academy of Science, 2008).  ASCs raise fewer controversial 
issues than ES cells.  However, ASCs are difficult to identify, isolate, maintain, and grow in the 
lab (The National Academy of Science, 2008).  Also, they are less flexible compared to ESCs 
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because they usually only differentiate to certain types of cells. Though experiments have shown 
some evidence for ASC flexibility or transdifferentiation in mice, they have not shown the same 
thing in humans (The National Academy of Science, 2008).    
Adult stem cells can be found in several places, including the bone marrow, umbilical 
cord blood, pancreas and brain. Currently, there are about 70 identified diseases that have been 
treated using non-ESCs, including breast cancer and sickle cell anemia (Earll, 2005) some of 
which will be discussed in Chapter-2.  
 
a. Adult Hematopoietic Stem Cells 
          Hematopoietic stem cells (HSCs) are the blood-forming stem cells.  They form white 
blood cells, red blood cells, and platelets (National Institute of Health, 2005). Recently, 
researchers have found through animal experimentation that HSCs exhibit some plasticity. Also, 
HSCs have the ability to undergo a process known as apoptosis, or programmed cell death, in 
which unneeded cells undergo self-destruction. Unfortunately, HSCs are hard to identify 
(National Institute of Health, 2005). They can be isolated from several sources such as bone 
marrow, cord blood cells, and the blood stream.   
The Bone marrow is a spongy tissue most often found in the breast bone (sternum), ribs, 
hip bone, skull, and spine. It is a big reservoir of white blood cells, red blood cells, and platelets 
(Abbott, 2003). Bone marrow transplantation can be used to treat various debilitating diseases of 
the blood and immune systems (Abbott, 2003). In this process, bone marrow is taken from living 
donors. There are three types of bone marrow donors. They can be autologous (the bone marrow 
is from the same person), syngeneic (from an identical twin donor), or allogeneic (from another 
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person who is genetically not identical to the recipient, but has a sufficient HLA match) (Abbott, 
2003).  
Peripheral stem cells are stem cells found in the arteries and veins. Growth of peripheral 
stem cells is stimulated via hormones. A process called apheresis can be used to collect the stem 
cells from the blood (Figure-4).  A needle inserted into both arms of the donor.  Then, the blood 
is taken from one arm and circulated through the machine to obtain the stem cells. The remainder 
of the blood is returned through a needle into the opposite arm. The process takes five hours and 
is painless (Abbott, 2003).  
 
 
 
 
 
Cord Blood Stem Cells are another source for HSCs.  Cord blood stem cells are derived 
from umbilical cords or a placenta after a baby’s birth. Usually, the cord and placenta are 
discarded at birth, however is increasingly common to ask the parents permission to freeze the 
cord blood in case the baby develops medical problems and needs a HSC infusion (Cord Blood 
Registry - Client Stories, 2004). 
There are two ways to store cord blood from newborn babies; one is public and the other is 
private family banking. (A) Family cord blood bank is exclusively used for family members, and 
Figure-4:  Peripheral Blood 
Hematopoietic Stem Cell 
Harvest by Apheresis 
(Przepiorka, 1996). 
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is not avalible to the public. There is a 75% chance that a baby’s cord blood stem cells are an 
acceptable match for his siblings. Usually, cord blood stem cells are twice as sucessful if used to 
treat a family member. (B) Public cord blood bank is used by any member of the public who may 
be in need of a transplant. If the family who donated the cord blood needs it, they are not 
guaranteed it will be available for them. Also, this approach is limited to certain hospitals in the 
United States (Viacord, 2007). 
 
b. Adult Neuronal Stem Cells  
Recently, neuronal stem cells (NSCs) were obtained from adult mice (Cassidy and Frisen, 
2001).  Previously, it was thought that our nerve cells were incapable of forming new neurons, 
but in the 1960s experiments showed that nerve cells can replenish themselves in specific parts 
of an adult’s brain.  Neurons and supporting cells (the glial and oligodendrocytes) were derived 
from NSCs.  These cells have the potential to cure neurodegenerative diseases such as 
Parkinson’s disease or Alzheimer’s (Cassidy and Frisen, 2001).  Neural stem cells are found in 
the wall of ventricles, which are lined by a single layer of cells known as ependymal cells, and 
beneath it is a narrow zone of tissue, known as the subventricular zone (Figure-5). Two types of 
neural stem cells were identified as ependymal cells and astrocytes. Unfortunately, within this 
region of the brain only 0.3% of the cells are stem cells, therefore NSCs are hard to isolate 
(Cassidy and Frisen, 2001).  
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Figure 5: A Section of a Mouse Brain Showing the Ventricle Wall From Which  
Neural Stem Cells Are Isolated.  (Cassidy and Frisen, 2001). 
 
 
Neural stem cells exhibit some plasticity, meaning they can generate different types of 
non-neural cell types if proper experimental conditions are met (Cassidy and Frisen, 2001). It 
was shown that multipotent stem cells can be induced to differentiate into nerve cells in vitro by 
using retinoic acid (Huettner, 2006).  
 
c. Adult Cardiac Stem Cells 
As is the case with the brain, the heart is formed of terminally differentiated cells, but it is 
not a terminally differentiated organ. The heart also contains stem cells which help in cell 
regeneration.  This is a promising opportunity for curing myocardial infarction.  Lin-negative, c-
kit-positive cells have cardiac stem cell properties, including a self-renewing, clonogenic, and 
multipotent properties, which is utilized within myocytes, smooth muscles, and endothelial cells. 
Upon cardiac stem cell injection to ischemic heart, these cells have the ability to reconstitute a 
well-differentiated myocardium (Beltrami et al., 2003).  Researchers suggest that the heart 
sustains a reservoir of stem cells that have the ability to make new cells in case of damage. Piero 
Anversa and his colleagues have discovered pockets of cardiac stem cells in the spaces between 
muscle cells in the heart of rats (Figure-6). After maintaining and growing these cells in cell-
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culture medium, the cells were injected into rats with damaged heart tissues. 70% of the 
damaged tissues were repaired within 20 days.  Also, previous studies conducted by Anversa 
have shown that cells from the bone marrow also have the potential to restore damaged heart 
muscle (Touchette, 2004).  
 
 
Figure 6: Picture of a Cluster of Cardiac Stem Cells (blue) Found Between  
Heart Muscle Cells (red) in Human Heart Tissue (Touchette, 2004). 
 
 
One of the paramount cardiac cells, the cardiomyocyte, is heart muscle which contracts to 
eject the blood out of the heart’s main pumping chamber (National Institute of Health, 2005).  
Two other types of cardiac cells are the vascular endothelial cell, which forms the inner lining of 
the blood vessel, and the smooth muscle cell, which forms the wall of a blood vessel. Under 
specific growth conditions, stem cells on culture dishes can develop into cardiomyocytes and 
vascular endothelial cells (National Institute of Health, 2005). 
Recently, Nature reported the existence of cardiac progenitor stem cells that were formally 
thought to be absent after birth. Those cells were found in the heart of newborn rats, mice, and 
humans, and have the potential of differentiating into fully mature cardiac tissue (Augs, 2005).  
Researchers identified cells called isl1+ progenitor cells in the tissues of newborn rats, mice, and 
human infants who were undergoing surgery for congenital heart defect.  If isl1+ cells were 
given the proper conditions, they have the ability to renew themselves and become a mature 
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cardiac muscle tissue. These cells, which are found in the atrium, are normally discarded during 
cardiac surgery, but can now be stored frozen.  Thus, infants can now use their own cardiac stem 
cells to correct a wide range of heart diseases (Augs, 2005). 
 
d. Adult Epithelial Stem Cells 
 
Epithelial stem cells are found in the lining of the digestive tract, and exist in deep crypts, 
the epidermis, and in hair follicles. Stratified squamous epithelia, such as the epidermis contains 
layers of cells known as keratinocytes, which migrate to the surface of the skin and form a 
protective layer. The basal layer, the one next to dermis, is the only place which contains cells 
that have the ability to divide. A number of these cells are identified to be stem cells, but the 
others are called transit amplifying cells. Keratinocytes move slowly outward through the 
epidermis as they mature (Encyclopedia Britannica 2008). 
Experimental evidence has also suggested that mammary cells exist, and their 
differentiation is the result of a sequence of a hierarchical process originating in a stem cell with 
the capacity of self-renewal.  But the lack of methods for mammary stem cell isolation has 
restricted the analysis of their properties and regulation. Mammary stem cells are continuously 
cycling population in normal adults, and they exhibit molecular characteristics suggesting a basal 
position in the mammary epithelium (Sting et al., 2006). 
 
e. Adult Mesenchymal Stem Cells  
         Adult mesenchymal stem cells (MSCs) are multipotent, and are found in the stromal 
fraction of the bone marrow. In fresh bone marrow, MSCs account for only 0.01-0.0001% of 
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nucleated marrow cells. Mesenchymal cell types include osteoblasts, chondrocytes and 
adipocytes. Some studies show that MSCs—easily collected and isolated-- possess some 
plasticity in which some MSCs form neural stem cells in vitro. Cells, which exhibit MSCs 
structures and cellular characteristics, were isolated from several sources including adult 
peripheral blood, adipose tissue, skin tissue, trabecular bone, fetal blood, and liver. In addition, 
umbilical cord blood and the chorionic villi of the placenta were shown to have MSC-like 
populations (Jackson et al., 2007) 
The transplantation of mesenchymal progenitor cells can possibly cure any genetic 
disorder of bone, cartilage and muscle; unfortunately clinical evidence for this transplantation is 
lacking. Allogeneic bone marrow transplantation is a way of engrafting functional mesenchymal 
progenitor cells, which has had a big impact on treating a disease known as osteogenesis 
imperfecta (Horwitz et al., 1999).  Researchers have also used a 6-hydroxydopamine (6-OHDA) 
animal model of Parkinson disease to determine the capability of the transplanted MSC to 
migrate and differentiate.  Results showed that rodents which underwent MSCs transplantation 
survive better in the 6-OHDA-induced damaged hemisphere compared to the un-lesioned side. 
This shows that 6-OHDA damage raises the viability of transplanted MSCs and attracts these 
cells from the other hemisphere (Hellmann et al., 2006). 
  
f.    Adult Intestinal Stem Cells 
 
The surface of the gastrointestinal tract is lined by a simple columnar epithelium which is 
folded to form invaginations called crypts. Each crypt has about 250 cells, depending on the 
species. The size and the organization of crypts are uniform within the gastrointestinal tract.  All 
major gut epithelial cells move towards the lumen of the gut as they mature, except Paneth’s 
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cells. The functional and differentiated cells are found on the vili or toward the top of the colonic 
crypt. Different experiments proposed that the number of stem cells per crypt is highly regulated; 
therefore, each stem cell can detect each other’s presence and respond properly (Booth and 
Potten, 2000). 
The intestinal epithelium is considered to be one of the most rapidly self-renewing tissues 
in adult mammals. Currently, researchers believe that there are 4-6 stem cells per crypt, and they 
are found at the +4-position immediately above the Paneth cells in the small intestine. 
Unfortunately, intestinal stem cells have not been isolated and purified due to their lack of 
unique markers and stem-cell assays. There are three types of differentiated intestinal cells, 
including enterocytes, goblet cells and enteroendocrine cells. These cells form from the transit-
amplifying cells at the crypt–villus junction. Paneth cells, are the fourth type of cells which 
resides at the crypt bottom. Until now, no stem cells have yet been discovered in the colon 
(Barker et al, 2007). 
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CHAPTER 2:  STEM CELL APPLICATIONS 
  
Stem cells hold promise for the treatment of many diseases because they are capable of 
dividing endlessly and developing into many different types of cells in the human body, thus 
they have many applications in the areas of scientific research and cell therapy.   During cell 
therapy, stem cells are used to produce cells and tissues that are required to repair body organs 
that have been damaged by disease or accidents.  Stem cells can be used to treat diseases such as 
cancer, spinal cord injuries, and Parkinson’s disease.  Whether from embryonic, adult, or 
umbilical cord stem cells, studies have demonstrated great potential for treating these diseases in 
animals, and even humans.   
In the most far reaching applications, pluripotent embryonic stem (ES) stem cells with 
wide differentiation potential could be used to create an unlimited supply of cells, tissues, or 
even organs to restore function without the use of toxic immunosuppression drugs and without 
the necessity of tissue matching compatibility, if the ES cells are genetically derived from the 
nucleus of the patient’s skin fibroblast cells (Chapman, 1999). Such cells, when used in 
transplantation therapies would not be immune-rejected.  In more traditional applications, bone 
marrow transplantation, when the transplant is not compatible, is associated with potential 
adverse effects, and it could become safe, cost effective, and be available for treating a wider 
range of clinical disorders like aplastic anemia and certain blood disorders, when the 
hematopoietic stem cells are derived from the same patient.  This would be especially helpful to 
people who have lost bone marrow function from radiation or exposure to toxic agents.  Growth 
and transplant of other tissues lost to disease or injury, for example, skin, heart, nervous system 
 28
components, and other major organs, are becoming a possibility (Applications of Stem Cells, 
2005). 
 
Stem Cell Treatment of Diabetes 
 Type I diabetes is a disease characterized by the destruction of insulin producing cells in 
the pancreas. Some treatments for these patients include human islet transplantation in an effort 
to restore insulin secretion.  But as with most transplants, a common problem occurs from 
complications from the immunosuppressive treatments required to prevent graft rejection.  The 
chance of graft rejection in a diabetic patient is increased because the immune system helped 
destroy this tissue in the first place.  And pancreatic tissue transplants are limited by the small 
numbers of donated pancreas available (Assady et al., 2001).  Stem cells potentially could be 
used to effectively resist immune attack as well as graft rejection.  The discovery of methods to 
isolate and grow human ES cells raises hopes of doctors, researchers, and patients that a cure for 
type I diabetes, and perhaps type II diabetes, is within reach.  In theory, ES cells could be 
cultivated and coaxed into developing into the insulin-producing islet cells of the pancreas.  With 
a ready supply of cultured stem cells at hand, the theory is that a line of ES stem cells could be 
produced for anyone requiring a transplant.  Before transplantation, the cells could be engineered 
to avoid immune rejection by maturing them into non-immunogenic cells so that they would not 
be rejected, and the patient would avoid the negative effects of immunosuppressant drugs.  
Although this technique has been successful in animals, having a sufficient supply of insulin-
producing cells for transplant into humans could be a long way off, but researchers have been 
making remarkable progress in their quest for it.  While some researchers have pursued the 
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research on ES stem cells, others have focused on isolating insulin-producing precursor cells that 
develop naturally in adult and fetal tissues (Stem Cells and Diabetes, 2007). 
 
Nervous System Diseases 
 Nervous system diseases result from a loss or damaging of nerve cells.  Scientists 
previously thought that mature nerve cells do not divide, and so there is no way to replace those 
neurons that are destroyed.  In Parkinson’s disease, nerve cells that make the chemical dopamine 
die.  In Alzheimer’s disease, cells produce highly neurotoxic beta-amyloid protein that kills 
nerve cells.  In amyotrophic lateral sclerosis, the motor nerve cells that activate muscles die.  In 
multiple sclerosis, the cells that protect nerve fibers are lost.  In spinal cord injury, brain trauma, 
and even stroke, many different types of central nervous system cells are lost or die.   
Scientists have now shown that neurons can be induced to regrow using either ES cells to 
differentiate into neurons, or using adult neural stem cells (NSCs) to divide into more neurons.  
The most effective treatment for these health issues comes from the possibility to create new 
nerve tissues from pluripotent ES cells (Applications of Stem Cells, 2005).  Numerous animal 
studies have shown that ES cells have the ability to differentiate into dopaminergic neurons in 
animal models for Parkinson’s disease.  Scientists have established various procedures to “coax” 
the cells to differentiate into neurons.  Some procedures include the treatment of cells with 
specific growth factors, the introduction of specific genes into the cells that cause differentiation, 
or the growth of ES cells in co-culture with other feeder cells to prompt differentiation.  Methods 
have also been established to identify specific markers within the transplanted cells to confirm 
that dopaminergic neurons have indeed been produced and are able to survive.  When the 
differentiated cells are transplanted into animals, the cells have been shown to survive for weeks, 
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and significant behavioral improvement has been recorded.  However the survival and function 
of these transplanted neurons after grafting needs to be assessed.  It is unknown how effective 
these procedures will be using human ES cells (Stem Cell Treatment Succeeds, 2006). 
 In addition to ES therapies, adult stem cells, which come from already developed nervous 
system tissue, have also been studied as a source of replacement cells for these types of 
problems.  Depending on the region of the nervous system that the cells are isolated, the adult 
stem cells can have slightly different properties, and scientists are working to establish the 
conditions for efficiently growing these stem cells and differentiating them into dopaminergic 
neurons.  Many different techniques have been studied; however, after transplantation of ASCs 
into animals, the survival of these cells is relatively low.  Scientists are attempting to determine 
the signals in the nervous system environment that are required to allow the transplanted cells to 
survive, integrate, and function correctly (Study Establishes, 2006). 
 Adult stem cells from bone marrow also surprisingly have the potential to be useful for 
the treatment of nervous system disorders due to their apparent ability to trans-differentiate into 
non-blood tissues.  Studies have shown that these bone marrow-derived cells are capable of 
changing into neuronal cells that can integrate in the brain.  However, other studies have 
suggested that the cells may actually fuse with cells already existing in the brain, so more studies 
are needed to determine the effectiveness these HSCs for neural therapies. 
 
Neural Stem Cells to Treat Spinal Cord Injuries 
An injured spinal cord loses its ability to regenerate myelin cells, an insulating layer 
around nerve fibers that transmits signals from the brain, leading to paralysis.  Each year, over 
11,000 Americans suffer from spinal cord injury, most commonly in traffic accidents.  Costs of 
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aid for the condition are approaching ten billion dollars per year.  Spinal cord injuries often have 
permanent effects since the myelin cells cannot regenerate on their own.  However, according to 
many animal studies, stem cells can repair damaged spinal tissue and help restore function in 
rodents with spinal cord injuries.  The treatments being given to the test subjects may eventually 
lead to new treatments for humans with spinal cord injuries (Stem Cell Treatment Succeeds, 
2006). 
 One study showed that in cases where stem cells restored myelin in the injured spine, rats 
showed some recovery and walked with more coordination.  Cells from the brains of adult mice 
were labeled with a fluorescent marker, enabling researchers to trace those cells after they were 
transplanted into rats whose spines had been crushed.  Adult NSCs transplanted into those rats 
only two weeks after the initial injury survived due to specific growth factors and immune-
suppressing drugs the researchers used.  More than one-third of the transplanted NSCs traveled 
along the spinal cord, fused with the damaged tissue, developed into the type of cells that were 
destroyed at the injured site, and produced myelin.  One important finding demonstrated by the 
study is that "the maximal effect of transplanting these cells is early after injury," says New York 
University School of Medicine professor Moses Chao, PhD.  "The timing of NSC application 
therefore is critical to successful therapy in the injured spinal cord" (Stem Cell Treatment 
Succeeds, 2005).  
 In a similar study, Hans Keirstead and his colleagues from Reeve-Irvine Research Center 
at UC Irvine, found that a human ES stem cell treatment was successful in restoring the 
insulation tissue for neurons in rodents treated within seven days after the initial injury.  The 
treatment led to a moderate recovery of motor skills, but the same treatment did not work for rats 
that had been injured for more than ten months (Study Establishes, 2006). 
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Both of these key studies show the potential of using NSC and ES cell-derived therapies 
for the treatment of spinal cord damage, and show the treatment is most effective during early 
stages of the injury.  One focus of future research will be to determine why stem cells 
transplanted late after the  injury fail to develop functioning tissues or survive (Vasich, 2005). 
 
Neural Stem Cells to Treat Parkinson’s Disease 
Stem cells also offer hope to patients with Parkinson’s disease, which is caused by the 
loss of dopamine-producing nerve cells in the brain.  If stem cells can be cultivated to become 
these dopamine-producing nerve cells, researchers believe that they could replace the lost cells 
(Garfinkel, 2005).  Stem cell based therapies for Parkinson's disease are not yet a common 
clinical procedure, but success has been achieved in animal models of the disease.  Scientists 
agree that more information and research is needed about the causes of Parkinson’s disease and 
the biology of stem cells before safe, effective and long-lasting therapies can be developed and 
practiced in humans.  Because a single, well-identified type of cell is affected in Parkinson’s 
disease (the substantia nigra) stem cells offer great potential for treatment.  The basis for such 
treatment would be to replace the cells that have died with other identical dopaminergic nerve 
cells, developed from stem cells (The Promise of Stem Cells, 2004).  Studies have shown that 
human stem cells transplanted into rats led to significant improvements in Parkinson’s like 
systems.  Post-mortem examinations showed that the stem cells had successfully developed into 
dopamine-producing cells (Ryan, 2004). 
 In recent human clinical trials, fetal brain tissues were transplanted into the brains of 
Parkinson's disease patients, and the results showed major and long-lasting improvements in 
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some of the patients (What is Parkinson's disease, 2008).  The trials also emphasized problems 
with these treatments, like the need to produce large amounts of uniform cells for transplantation 
into patients.  Stem cells provide the greatest hope for treatment since dopaminergic-like cells 
have already been obtained from both ES and fetal brain stem cells (What is Parkinson's disease, 
2008). 
 
Neural Stem Cells to Treat Alzheimer’s Disease 
A research team led by a University of Central Florida professor Kiminobu Sugaya, 
found that treating bone marrow cells in with bromodeoxyuridine, a compound that incorporates 
into replicating DNA, made adult human stem cells more likely to develop as brain cells after 
they were implanted in adult rat brains.  Sugaya and his colleagues hope to eventually show that 
stem cells transplanted from a patient’s blood or bone marrow will be an effective treatment for 
Alzheimer’s and other neurological diseases because they can replace cells that die from those 
ailments. The researchers are working with a $1.4 million grant from the National Institutes of 
Health (Binette, 2005).  "By using a patient’s own stem cells instead of embryonic stem cells, 
we’re able to avoid the ethical concerns many people have about stem cell research," Sugaya 
said.  "We also don’t have to worry about the immune system rejecting the new cells, because 
they come from the same patient."  In the same experiments, they reported successes in culturing 
stem cells from bone marrow to become neural cells after they were implanted in rats.  
Improving the chances of implanted cells functioning as neural cells is demonstrating 
possibilities for the treatment of Alzheimer’s disease (Binette, 2005). 
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Neural Stem Cells to Treat Stroke 
Strokes cause temporary loss of blood supply to the brain which results in areas of brain 
tissue dying, causing the loss of certain bodily functions such as speech and motor skills.  Neural 
stem cells offer new possibilities for brain tissue regeneration which could help stroke victims.  
However, there are still major limitations in delivering these cells to the brain.  While NSC 
transplantation has been proven to improve conditions in rats with stroke damage, little reduction 
in lesion volume has been observed (Stem Cell Therapy Studies For Stroke, 2008).  In one study 
a neurobiologist from the Institute of Psychiatry, Dr Modo, explains: "We propose that using 
scaffold particles could support NSCs in the cavity to re-form the lost tissue and provide a more 
complete functional repair. The ultimate aim is to establish if this approach can provide a more 
efficient and effective repair process in stroke" (Brain Tissue,2008).  Thus when using neural 
stem cells to treat brain disorders, the future of the field may involve using scaffolds to provide a 
substrate for the transplanted cells to grow on. 
 
Stem Cell Treatment of Damaged Heart Muscle 
 New studies have shown that stem cells might be used to treat patients who have suffered 
from a heart attack.  By injecting bone marrow stem cells into damaged tissues of the heart, new 
vascular endothelium, cardiomyocytes, and smooth muscle cells can be formed.   
One animal study performed on mice treated with bone marrow stem cells showed that 
the newly formed tissues occupied sixty eight percent of the damaged area only nine days after 
treatment, and treated mice survived in much greater numbers than the mice that did not receive 
any treatment (Can Stem Cells Repair a Damaged Heart, 2006).   
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A human study performed at the American College of Cardiology Innovation in New 
Orleans showed that heart attack patients who received a new intravenous mesenchymal stem 
cell therapy called Provacel, experienced a lower number of adverse effects such as cardiac 
arrhythmias, and showed signs of significant improvements in heart, lung and global function, 
compared to those patients who received a placebo.  Provacel is a treatment containing adult 
mesenchymal stem cells pre-formulated for intravenous delivery.  Patients were administered a 
dose of either Provacel or placebo within ten days of having a heart attack.  Mesenchymal stem 
cells are found in adult bone marrow, and have the potential to develop into mature heart cells or 
new blood vessels.  The “MSCs” are obtained from healthy adult volunteer bone marrow donors 
and are not derived from a fetus, embryo, or animal.  Because the cells are in such an early stage 
of development, it is believed that they do not cause an immune rejection when transplanted in a 
patient.  Similar to type O blood, MSCs can be donated without tissue type matching to a 
specific patient. Another benefit of this type of stem cell therapy is that it can be given to patients 
through a simple intravenous injection.  Other therapies require delivery of stem cells directly to 
the site of the damaged tissue through catheterization or open surgical procedures (Heart Attack 
Patients, 2007).   
Dutch researchers at the University Medical Center Utrecht and the Hubrecht Institute 
have developed a procedure to grow large numbers of adult stem cells from human hearts and 
have them create new heart muscle cells.  The stem cells are derived from material left over from 
open-heart surgeries.  The researchers used a method to isolate the stem cells from this material 
and culture them in the laboratory, which are then allowed to develop. The cells grow into fully 
developed heart muscle cells that are able to contract rhythmically, respond to electrical activity, 
and even react to adrenaline (Heart Derived Stem Cells, 2008). 
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Stem Cell Treatment of Primary Immunodeficiency Diseases 
  Pluripotent stem cells could potentially be used in the treatment of virtually all primary 
immunodeficiency diseases.  Presently, more than 70 different forms of deficiencies of the 
immune system have been recognized.  These are among the most complicated diseases to treat.  
Diseases such as severe combined immunodeficiency disease, Wiskott-Aldrich Syndrome, lupus, 
and the immune deficiencies suffered as a result of acquired immune deficiency syndrome 
(AIDS) are just a few of these forms.  These diseases are characterized by a high susceptibility to 
infection and are often associated with anemia, arthritis, and diarrhea.   
 However, the transplantation of stem cells engineered with the normal gene could result 
in recovery of the immune function.  Successful transplantation could increase the life span and 
quality of life for these people (Applications of Stem Cells, 2005).  Researchers from the UCLA 
AIDS Institute and the Institute for Stem Cell Biology and Medicine have demonstrated that 
human embryonic stem cells can be genetically manipulated and “coaxed” to develop into 
mature T-cells.  T-cells are one of the body's main defenses against infection and disease, and are 
lowered in patients infected with HIV.  The new T-cells create possibilities for a gene therapy to 
combat AIDS.  The study suggests that it is possible to convert human embryonic stem cells into 
blood-forming stem cells that can differentiate into the helper T-cells that HIV specifically 
targets.  The results mark the first time that scientists have been able to derive T-cells out of 
human embryonic stem cells.  In their study, the researchers cultured human embryonic stem 
cells grown on mouse bone marrow support cells, which in turn converted them into 
blood-forming cells. Those cells were then injected into a human thymus gland that had been 
implanted in a mouse, and the thymus then changed those blood-forming cells into T-cells 
(Researchers Develop T-cells, 2005). 
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Stem Cell Treatment of Cancer 
 Since stem cells can be damaged in certain cancer treatments, CTCA hospitals developed 
techniques to add healthy stem cells back into your body after damaging cancer-fighting 
chemotherapy treatments take place.  At the present time, adult bone marrow stem cells are used 
to treat patients following high doses chemotherapy. These treatments using stem cells may also 
be used for patients who have had radiation treatment for their cancer.  Unfortunately, bone 
marrow cells are somewhat limited in their capacity to restore immune function completely, so 
researchers are working to develop injections of properly-differentiated stem cells that would 
return the complete functionality of the immune system to patients undergoing bone marrow 
transplantation.  More successful stem cell recovery would enable the use of very toxic, and 
effective chemotherapeutic procedures that can not currently be utilized due lack of an ability to 
restore bone marrow and immune function following their use (Stem Cells Used in Cancer 
Therapies, 2008). 
 There are 3 types of stem cell transplants: Autologous stem cell transplants, allogeneic 
stem cell transplants, and syngeneic stem cell transplants.  In autologous stem cell transplants, 
the patient serves as their own donor. Bone marrow or peripheral blood stem cells are taken from 
the patient, frozen until needed, then given transplanted back into the patient after they have 
received high doses of chemotherapy, radiation or both to destroy cancer cells.  An allogeneic 
stem cell transplant occurs when bone marrow is replaced with new, healthy bone marrow or 
peripheral blood stem cells from another tissue matched donor.  Most allogeneic stem cell 
transplants have been performed using stem cells from the bone marrow, but the use of 
peripheral blood stem cells is increasing. In a syngeneic stem cell transplant, a patient receives 
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stem cells from their identical twin. Since identical twins aren’t very common, syngeneic 
transplantations are rare. Because identical twins have the same genes, they also possess the 
same human leukocyte associated antigens which help dictate histocompatibility, so there is less 
chance of the transplant being rejected (Stem Cell Transplantation, 2008). 
  
 Stem cells have provided new hope for many patients who suffer from a large range of 
diseases that currently have little or no therapeutic treatments.  Advancements in this particular 
medical field have shown the potential of many different types of stem cells.  Some procedures 
like bone marrow transplant have already been a proven to be a safe and effective method of 
treating cancer patients, while new studies strive to develop treatments for spinal cord injuries, 
Parkinson’s disease and many other health issues.  Due to the ability to produce an unlimited 
amount of these cells from single lines of stem cells, researchers believe that many of the new 
procedures will become feasible and cost efficient methods for treating patients.  Even though 
many of the hopeful applications of stem cells have not been perfected of proven safe, the 
potential of these cells appear to be limitless.    
  
 
Chapter-2 Bibliography 
 
 
"Applications of Stem Cells" (2005) ISCID Encyclopedia of Science and Philosophy. 
http://www.iscid.org/encyclopedia/applications_of_stem_cells 
 
Assady, S., Maor, G., Amit, M., Itskovitz-Eldor, J., Skorecki, K.L., and Tzukerman, M. (2001). 
Insulin production by human embryonic stem cells. Diabetes. 50. 
http://www.diabetes.org/Diabetes_Rapids/Suheir_Assady_ 06282001.pdf 
 
 39
Binette, Chad (2005) "UCF stem cell research may hold promise for treating Alzheimer’s 
disease." Innovations Report. 14 Feb. 2005. http://www.innovations-
report.com/html/reports/life_sciences/report-40232.html 
 
"Brain Tissue Could Be Regenerated After Stroke By Inserting Microscaffolding And Stem 
Cells, Animal Study Suggests." Science Daily. 10 Apr. 2008. 
http://www.sciencedaily.com/releases/2008/04/080410080230.htm 
 
"Can Stem Cells Repair a Damaged Heart" (2005) Stem Cell Information National Institutes of 
Health.  7 Oct. 2006. http://stemcells.nih.gov/info/scireport/chapter9.asp 
 
Chapman, Audrey (1999) "Stem Cell Research and Applications." Nov. 1999. 
http://www.aaas.org/spp/sfrl/projects/stem/report.pdf 
 
Garfinkel, Susan (2005) "Stem Cells and Parkinson’s Disease." International Society for Stem 
Cell Research. 31 Mar. 2005. 8 http://www.isscr.org/public/parkinsons.htm 
 
"Heart Attack Patients Treated With Novel Stem Cell Therapy Experience Significant 
Improvement in Heart and Lung Function." Science Daily. 28 Mar. 2007. 
http://www.sciencedaily.com/releases/2007/03/070327144302.htm 
 
"Heart Derived Stem Cells Develop Into Heart Muscle." Science Daily. 23 Apr. 2008. 
http://www.sciencedaily.com/releases/2008/04/080410080230.htm 
 
"Researchers Develop T-cells From Human Embryonic Stem Cells, Raising Hopes For A Gene 
Therapy To Combat AIDS." Science Daily. 5 July 2005. 
http://www.sciencedaily.com/releases/2006/07/060705083338.htm 
Ryan C (2004) “Stem Cell Therapy for Parkinson's”.  BBC News. 
http://news.bbc.co.uk/1/hi/health/3853791.stm 
 
"Stem Cell Therapy Studies For Stroke, Cerebral Palsy Prepare For Clinical Trials." Science 
Daily. 30 Jan. 2008. http://www.sciencedaily.com/releases/2008/01/080129160714.htm 
 
"Stem Cell Transplantation" (2008) Cancer Compass.  
http://www.cancercompass.com/cancer-treatment/stem-cell-transplantation.htm 
 
"Stem Cell Treatment Succeeds In Spinal Cord-injured Rats." Science Daily. 30 Mar. 2006. 
http://www.sciencedaily.com/releases/2006/03/060328224824.htm 
 
"Stem Cells and Diabetes." Stem Cell Information National Institutes of Health. 7 Oct.  
2007.   http://stemcells.nih.gov/info/scireport/chapter7.asp 
 
"Stem Cells Used in Cancer Therapies." Cancer Treatment Centers of America. 2008. 
http://www.cancercenter.com/stem-cells.htm 
 
 40
"Study Establishes Safety Of Spinal Cord Stem Cell Transplantation." Science Daily. 20 July 
2006.   http://www.sciencedaily.com/releases/2006/07/060720103810.htm 
 
"The Promise of Stem Cells: Parkinson's Disease." University of Minnesota Stem Cell Institute. 
1 Oct. 2004. http://www.stemcell.umn.edu/stemcell/stemcell101/dzfacts/parkinsonsdisease.htm l 
 
Vasich, Tom (2005) "Stem cell treatment improves mobility after spinal cord injury." Medical 
News Today. 11 May 2005. http://www.medicalnewstoday.com/articles/24159.php 
 
"What is Parkinson's disease and can stem cells help?" Euro Stem Cell. 2008.  
http://www.innovations-report.com/html/reports/life_sciences/report-40232.htm 
  
 
 41
CHAPTER-3:  STEM CELL ETHICS 
 
Just because we can work with stem cells, should we?  In this chapter, the stances of the 
world’s five major religions (Christianity, Islam, Judaism, Hinduism, and Buddhism) towards 
stem cell ethics will be analyzed and discussed in more detail.  During human history, so-called 
scientific progress has given rise to controversy for scientific and religious communities, but 
society has to balance religion and science to determine the ethics and morality of new 
advancements within their context (Mannoia, 2004).  And another question arises whether 
society is fully knowledgeable of the stem cell controversy.  For this, we will investigate media 
coverage of this issue. 
 Not until the summer of 2001 did the media pay large amounts of attention to the stem 
cell issue; therefore, it was not surprising when surveyed in the fall of 2000, only 20% of 
Americans reported following the issue either "very closely" or "fairly closely." This percentage 
increased to 38 % in July 2001 before US President Bush's August 9, 2001, decision to limit 
federal funding for embryo stem-cell research. In September 2002, a year after Bush's decision, 
13% of respondents reported having seen, read, or heard "a lot" about the issue, whereas 46% of 
respondents reported knowing "not much" or "nothing at all," showing that overall public 
attention had declined from 2001 levels, parallel to a drop in media attention (Nisbet, 2004). 
“Polls show that the public doesn’t know much about the science or the policy surrounding stem-
cell research, and that means they really haven’t solidified their opinions,” said Matthew Nisbet, 
an assistant professor of journalism and communication at Ohio State University (Grabmeier, 
2004). 
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Politics and religion play a central role in influencing the public’s ethics of stem cell 
research.  Major religious authorities in the U.S. have influenced politicians on their decisions 
regarding the stem cell debate.  In the United States, the major stem cells ethics dilemma started 
back in 1998 when the first human stem cells were extracted from an embryo.  Since then, 
several questions have been raised, including: 
• When does human life begin? (Bhikkhu, 2007)   
• Is it morally allowable to use living human embryos for the preparation of embryonic stem 
cells (ESCs)?  
• Is it morally acceptable to engage in “therapeutic cloning” for the purpose of producing 
human embryos and then destroying these embryos to obtain their stem cells?  
• Is it morally permissible to use ES cells, and the differentiated cells obtained from them, 
which are supplied by researchers or are commercially accessible? (Correa and Sgreccia, 
2000) 
• Is it morally licit to sacrifice an embryo for its stem cells that can save, or treat people 
afflicted with debilitating diseases, or is the cost of doing this too high?   
• Is it permitted to fertilize ova to create an embryo solely to use its stem cells?  
• Is it ethical to use the tissues from aborted fetuses for medical treatments? (Eisenberg, 2006) 
It is obvious from media reports and their effects on political discourse that religious 
beliefs have a big influence on the stem cells issue. Furthermore, this debate demonstrates the 
connection between science and religion  (Mannoia, 2004). Everything “new” that appears in a 
modern and high-tech society has to make peace with everything “old” that already exists. While 
science cares about answering the question of how everything works, religion on the other hand 
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tries deals with what is right and acceptable (Tyagananda, 2002).  Generally, religious traditions 
refer to sacred texts and theological teachings to express their thoughts on a matter. This leads to 
the presence of a wide-spectrum of opinions and ideas even within one tradition, since the 
current issues were not dealt with before in the sacred ancient texts of religious traditions. 
Therefore, giving a religious perspective on a matter now includes interpretations and diverse 
viewpoints (Tyagananda, 2002).  
Where should the red-line be drawn in this complex matter between our desire as 
scientists to discover new advancements to cure different diseases, and as human being with our 
ethics and values?  What about our moral commitment to heal the sick and relieve suffering due 
to an injury or illness (Chapman et al., 1999)?  The answers for these questions in this chapter 
will be based on what each major religion believes, including disagreements within a religion 
(Chapman et al., 1999). 
 
Embryonic Stem Cells Ethics  
Research involving embryonic stem cells (ESCs) is the most debatable aspect of the 
entire stem cell issue.  It has caused huge controversies among religious leaders and politicians, 
so in this section the view of the five-major religions on ESCs will be analyzed in more detail.  
ESCs, as mentioned in earlier chapters, are derived from the inner cell mass of a 5-6 day old 
blastocyst, so a key question to be answered is: should we equate hESCs to human embryos (de 
Wert and Mummery , 2003)?  Some religions believe that life begins at conception.  Others 
believe life begins when the primitive streak, the precursor of the spinal cord in embryos, 
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develops, while others believe life begins after birth (Derbyshire, 2001).  In Nature Reviews: 
Genetics, John Robertson divides the ethical objectors to embryonic research into three main 
groups:  
A. Those who consider the embryo as a person with full rights and interests, thus any 
destruction of an embryo would be considered as murder. 
B. Those who believe that although an embryo lacks the capacity to be considered a “person,” it 
still has the potential to become a person; therefore, it has a special representative value and 
needs to be protected in respect of human life.  
C. Those who believe the embryo is just a group of cells (Derbyshire, 2001).  Such individuals 
might be considered as scientific materialists. This group will not associate an embryo with 
personhood or religious significance, but rather will consider it as a beneficial resource 
(Mannoia, 2004).  
 
Christian Stance on Embryonic Stem Cells 
Christianity has the largest number of followers in the world, around 2.1 billion people 
(Major Religions of the World Ranked by Number of Adherents, 2005). Christianity has many 
denominations and schools of thought, so no one speaks for all teachings of its traditions 
(Bhikkhu, 2007). In general, however, Christianity teaches that life begins at conception, when 
an egg is fertilized by a sperm. The Roman Catholics, Eastern Orthodoxers, and Southern 
Baptists believe that from conception onward, the embryo has a soul and thus needs to be 
treated as a human being (KohsL, 2008).  This belief is confirmed by the Catholic Pope and his 
bishops: The human embryo is precious and is treated as a person from the time of fertilization; 
it should not be destroyed or seen as a disposable tissue that might be used for research, and no 
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embryos should be created for research purposes (Shannon, 2006). Therefore, by many 
Christian jurists, using embryonic stem cells in research is morally unacceptable.  In his 
statement to the National Bioethics Advisory Commission (NBAC), the Roman Catholic 
layman Edmund Pellegrino explains: "In the Roman Catholic view, human life is a continuum 
from the one-cell stage to death.  At every stage, human life has dignity and merits protection. 
Upon conception, the biological and ontological individuality of a human being is established" 
(KohsL, 2008). The U.S. Roman Catholic Bishops are against ESC research, and described it as 
"immoral, illegal, and unnecessary" (Religious Views on Stem Cell Research, 2001). 
The Anglican-Episcopal tradition has argued that embryos do not have the capacity to 
become a distinct individual with the ability to develop into a human being until the fourteenth-
day of gestation, when the primitive streak forms and the embryo can no longer split into 
several individuals (KohsL, 2008).   Eastern Orthodoxy states that the embryo and the adult are 
both humans, regardless the different stages of development.  However, Eastern Orthodoxy 
allows research only on existing human ESC lines and not on human embryos for therapeutic 
purposes (Walters, 2004).   
The main Christian Catholic objection to ESC research is demonstrated by the reaction 
of U.S. Catholic bishops towards President Bush's August 9, 2001 law when he decided to allow 
a limited federal funding for ESC research.  Bishop Joseph A. Fiorenza, President of the U.S. 
Catholic Conference of Bishops, issued a statement on August 10 calling the decision as 
morally unacceptable: "The federal government, for the first time in history, will support 
research that relies on the destruction of some defenseless human beings for possible benefit to 
others.  However, such a decision is hedged with qualifications, it allows our nation's research 
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enterprise to cultivate a disrespect for human life” (American Catholic Organization, 2006).  
While the Roman Catholic Church is against embryo research, the Unitarian-Universalists, the 
Episcopal Church, the Evangelical Lutheran Church, the United Methodist Church, and the 
Church of Jesus Christ of Latter Day Saints have no official position (Derbyshire, 2001). 
In summary, Christianity can be divided into three categories with respect to its stance 
on ESCs:  
A. Those who are opposed to human ESCs research (Catholic).  
B. Those who limit the use of embryos until the fourteenth-day, but include the use of 
blastocysts to provide ES cells (Anglican-Episcopal). 
C. Those who accept the use excess embryos from infertility treatments for ES research 
(Anglican-Episcopal, Unitarian, Lutheran, Methodist, and Latter Day Saints) (KohsL, 2008). 
This topic will be discussed later in the chapter in the section on IVF ethics.  
Islamic Stance on Embryonic Stem Cells 
Islam, as opposed to Christianity, is more flexible when it comes to human ESCs 
because the status of the embryo (when life begins) is different in Islam than it is in Christianity.  
Islam has the second largest number of followers after Christianity, with about 1.5 billion 
people.  The main sub-groups within Islam are Sunni and Shi’a (Major Religions of the World 
Ranked by Number of Adherents, 2005).  Islam bases its laws on two sources, the Qur’an (the 
Islamic religious text) and the Shari’ah (Islamic law which teaches Muslims how to worship 
God according to the Qur’an and the Prophet Muhammad).  Islamic laws are flexible and are 
supposed to be analyzed under current times to deal with new issues (Weckerly, 2002).   
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Among Muslims, one cannot speak in consensus on the question of embryonic moral 
status.  As a result, various scholars and religious leaders present their opinions, but no single 
individual or group exercises a high authority in matters of practice (Walters, 2004).   Many 
Islamic scholars designate that “ensoulment” of the fetus does not occur until the fourth month of 
pregnancy (Weckerly, 2006). In both Sunni and Shi’a tradition, ESC research is permitted, as 
Abdulaziz Sachedina testifies, "It is correct to suggest that a majority of the Sunni and Shi'ite 
jurists will have little problem in endorsing ethically regulated research on stem cells that 
promises potential therapeutic value" (KohsL, 2008). 
The Shari’ah laws make a distinction between actual and potential life, thus the embryo 
as a potential human being is not a human being until ensolument occurs under Islamic law.  So 
destroying an embryo is not murder, and the use of human ESCs for research will not violate 
Islamic laws (Weckerly, 2006).  ESC research is taking place in Iran, where a big population of 
Shi’a Muslims exists (Bhikkhu, 2007).  In both Sunni and Shi’a traditions, human ESC research 
is encouraged if it is being done to produce tissues, valves, and new organs ultimately for 
treatment purposes (Bhikkhu, 2007). 
 
Judaic Stance on Embryonic Stem Cells  
 Jewish traditions teach that human bodies belong to God, and that they are on loan for a 
life-duration on earth.  God, as the owner of human bodies, is able to, and does impose, 
conditions on the use of human bodies. As a result, there is a duty to seek new cures for human 
diseases (Dorff, 2001). Judaism accepts artificial ways to overcome illnesses. Judaism considers 
physicians as agents of God in the continuing act of healing (Dorff, 2001).  The task of healing in 
Judaism is not only permitted, it is mandated (Walters, 2004).   According to Orthodox Judaism, 
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embryonic stem cell research is not debatable at all, as indicated by Rabbi Yosil Rosenzweig of 
Beth Jacob Congregation synagogue in Kitchener.  Stem cell research in Judaism is acceptable 
for two reasons:  
A. Based on the Talmud, rabbinic interpretations of the Scriptures and how to apply 
commandments in the contemporary world, the embryo is not considered a human being 
at conception.  
B. Judaism does not count the embryo as a human being until it is 41 days-old; before that 
time the embryo is just a living tissue (Bhikkhu, 2007).   
 
Therefore, within the Jewish tradition, the embryo is owed protection after 40 days of 
gestation, but not before.  Rabbi Moshe Dovid Tendler states that: "There are two prerequisites 
for the moral status of the embryo as a human being: implantation and 40 days of gestational 
development. The proposition that humanhood begins at zygote formation, even in vitro, is 
without basis in biblical moral theology" (KohsL, 2008). At the same time, Judaism is against 
creating human embryos specifically for scientific research purposes (Bhikkhu, 2007).  However, 
the Jewish religious tradition focuses on not just research, but saving lives, and strongly supports 
human ESCs.  Several commentators from this tradition have emphasized the ultimate goal of 
human ESCs to save lives (Walters, 2004). 
As described in Jewish tradition, the embryo is not considered as human at the time of 
fertilization; instead, the virtually-unanimous view is that the human embryo is "like water" 
during the first 40 days of its development, in the words of Moshe Tendler, an Orthodox scholar.  
The Judeo-Biblical tradition does not hold any moral status to an embryo before the 40-days of 
gestation.  Some look at the moral status of early embryos as male and female gametes, and the 
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destruction prior to implantation as being the same moral significance as the "wasting of human 
seed" (Walters, 2004).  
 
Hindu and Buddhist Stances on Embryonic Stem Cells 
Hinduism and Buddhism (the so-called Eastern religions) have a lot in common. Unlike 
other religions, Hinduism and Buddhism have no central authority (like a Church) to speak on 
ethical dilemmas. Therefore, there is no clear-cut answer from Hinduism and Buddhism on ESCs 
ethics (Keown, 2004). 
Hindus believe that life starts at conception.  As a result, the fetus is considered as a 
person at that moment (Castillo, 2006).  In the Hindu tradition, conception is the beginning of a 
soul's rebirth from a previous life.  Some Hindu traditions place the start of personhood between 
three and five months of gestation, while a few believe that incarnation can occur as late as the 
seventh month, both of which allow using embryos to derive ES cells (General Positions on Stem 
Cell Research and When Personhood Begins, 2006), however it is difficult to come up with an 
exact answer since there is no single authoritative voice that can speak for the entire tradition or 
community (Tyagananda, 2002). 
 In an article he wrote, Tyagananda (a Hindu monk), presents “a” Hindu perspective 
rather than “the” perspective on issues related to stem cell research (Tyagananda, 2002).  Based 
on Hinduism, the human soul is the spiritual component of the personality, and it is different 
from the mind and body. Hindus also understand that life and death come together, and cannot be 
separated from each other.  Thus, Tyagananda came up with the food-chain analogy; the survival 
of one living organism is often at the expense of another living creature (Tyagananda, 2002).  
For example, if a hungry lion eats a deer, it is not considered an un-ethical act or bad karma. 
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Therefore, destroying life, one’s own or somebody else’s, is bad karma unless it was done in an 
unavoidable circumstance and for the greater good (Tyagananda, 2002). Tyagananda questions:  
Is the destruction of embryos for stem cell research considered an “unavoidable circumstance” 
and an act “done for greater good”?  If so, then Hindus will accept ES research as ethically 
justified (Tyagananda, 2002).   
Also, there can be other concerns that might test the restrictions of an ethical 
consideration.  For example, what would be the source of stem cells?  From the Hindu 
perspective, it will be acceptable if the embryo donation is charitable and for scientific purposes, 
but not for commercial purposes (Tyagananda, 2002).  Another question is: Who would be the 
beneficiaries from such research?  In the Hindu tradition, if the benefits of the stem cell research 
were distributed equally, not only for wealthy who could afford the high price of advanced stem 
cell medicine, then the stem cell research would not be considered un-ethical (Tyagananda, 
2002).  
Another source that also helped to clarify the stance of Hinduism on stem cell research is 
The Hindu Endowments Board of Singapore, which indicated its acceptance of stem cell 
research within certain time limits (Walters, 2004), using embryos no more than 14 days old.  
Buddhism looks at the intentions behind human ESC research to determine its morality.  
For example, if the intention is to cure ill people, then the use of ESCs is considered ethical.  On 
the other hand, if the research on ESCs was performed for the sake of money, then it is unethical 
(Walters, 2004). The Buddhist religion is based on the principle of “ahimsa” (non-harming); 
therefore, Buddhism has serious worries about any scientific technique that might involve the 
destruction of life.  Such acts are prohibited by the First Precept of Buddhism which prohibits 
causing death or injury to living creatures (Walters, 2004).  Buddhism believes in the central 
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virtues of knowledge “prajña”, compassion “karua”, and its long tradition of practicing medicine 
(Keown, 2004). Buddhism believes that life starts at conception and agrees with Hinduism on the 
re-birth theory (General Positions on Stem Cell Research and When Personhood Begins, 2006). 
Since Buddhism believes in the re-birth in which the new being bearing the karmic identity of a 
recently deceased individual, the embryo has the same moral respect as an adult (Keown, 2004) 
so Buddhism considers any intentional destruction of embryos to obtain human ESCs as morally 
not permitted (Keown, 2001). 
 
In Vitro Fertilization Ethics  
 Currently, the main source of ESCs is the surplus of embryos created in vitro fertilization 
(IVF).  In the process of IVF, egg and sperm donated by a couple are united in a test tube, and 
the embryo is cultured for 5-6 days to the blastocyst stage, then is usually implated into the 
uterus of a woman for reproductive purposes.  Because the process is not always successful, 
extra embryos are created for the couple.  Once the couple has enough children, the excess 
embryos are either destroyed or are donated to another couple (Siddiqi, 2002). The remaining 
embryos could be either been frozen or destroyed.  Usually, the couple is given four options for 
their “spare embryos”: 
A. Have the excess embryos discarded. 
B. Donate the excess embryos to infertile couples (embryo adoption).  
C. Donate the excess embryos for research.  
D. Preserve the excess embryos under very low temperature for possible use in the future 
(Robinson, 2005).  
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Few parents are willing to give their embryos to another couple for various emotional 
reasons, and few couples are willing to receive them for emotional reasons (Robinson, 2005). 
Preserving embryos at a very low temperature (in liquid nitrogen) can be very expensive, so most 
couples choose to discard them (Robinson, 2005).   
The Muslim stance on IVF is clear.  As mentioned before, according to the Shari'ah laws 
a distinction should be made for the embryo between actual and potential life.  And at the same 
time, there has to be some differences between a fertilized egg in a dish and a fertilized egg in a 
womb (Siddiqi, 2002).  No embryo will survive to adulthood unless placed in its natural 
environment, the womb, so research using these embryos, surplus embryos from IVF, is 
permitted by Muslims especially if the goal is to cure disease.  Islamic scholars observe that if 
these embryos were treated as a full human, it would have been forbidden to produce them in 
surplus and destroy them later (Siddiqi, 2002).  Islam prohibits surrogate parenting or human 
embryo adoption due to the significance of determining a child’s true parentage and inheritance 
rights.  Therefore, the Qur’an encourages using excess embryos for research purposes, since 
under Islamic law surplus embryos can only be used by the couple that created them (Weckerly, 
2002). The Washington-based Islamic Institute stated, “Under [the] Islamic principle of the 
‘purposes and higher causes of the Shari’ah,’ we believe it is a societal obligation to perform 
research on these extra embryos instead of discarding them” (Weckerly, 2002).  The Jewish 
stance is also clear.  In Judaism, using IVF embryos is permitted prior to forty-days of gestation, 
because as discussed earlier, at this stage, the fetus lacks "humanity" (Eisenberg, 2006). 
As to the Catholic stance, stem cells produced via IVF are condemned.  In his 1995 
encyclical The Gospel of Life, Pope John Paul II wrote: "Human embryos obtained in vitro are 
human beings with rights; their dignity and right to life must be respected from the first moment 
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of their existence.  It is immoral to produce human embryos destined to be exploited as 
disposable 'biological material'" (Filteau, 2007). On the other hand, the Presbyterian Church 
(U.S) and the Methodist Church have no objections on conducting research or using excess 
embryos produced by IVF.  In his address to the UN Mission Ambassadors on the cloning 
concerns, Jim Winkler, an official of the United Methodist Church, states that "The Church 
supports embryonic stem cell research using embryos leftover from in-vitro fertilization 
procedures, but NOT cloning" (KohsL, 2008).  
As indicated before, the Hindu Endowments Board of Singapore indicated its acceptance 
of stem cell research within certain time limits, using embryos no more than 14 days old.  Hindus 
will most likely support the use of surplus IVF embryos that are no longer needed for 
reproduction purposes so long as the embryos are younger than 14 days. Also, ESCs derived 
from 5 day old frozen embryos can be used to establish ES cell lines (Walters, 2004).  But 
according to Buddhism, it is immoral to use the excess embryos or frozen embryos created via 
IVF regardless of the fact that they will be destroyed anyway (Keown, 2004). 
 
Somatic Cell Nuclear Transfer Ethics  
Somatic cell nuclear transfer (SCNT), otherwise known as “therapeutic cloning,” as 
discussed in Chapter-1 is a process where a nucleus is removed from an adult skin fibroblast cell 
and injected into an enucleated egg for purposes of deriving embryos and ES cells genetically 
identical to the original patient.  SCNT could be performed for therapeutic purposes (using ES 
cells for treating a disease) or for “reproductive cloning” in which the new embryo is implanted 
into a surrogate mother and would give birth to a child genetically identical to the donor of the 
nucleus.  Many Islamic scholars consider cloning embryos for the therapeutic purposes to be 
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acceptable (Weckerly, 2006).  But most Christian leaders strongly oppose therapeutic cloning 
(Frazzetto, 2004).  
The stance of Judaism on therapeutic cloning is similar to Islam. According to the Torah, 
Jews have an obligation to search for knowledge, and scientific knowledge is granted high 
value. "Our theological predisposition is not only to welcome, but to aggressively pursue 
new technologies that improve our lives and our world" (Frazzetto, 2004).  There is no clear 
position on therapeutic cloning from the Hindu perspective. However, Dr. Muthuswamy said the 
general opinion was in favor of allowing “therapeutic cloning” (The Hindu, 2006).  Also, 
Hinduism makes a distinction between the destruction of a preimplantation embryo (permitted) 
and abortion (condemned), by accepting the research on preimplantation embryos if the goal was 
to save lives (Walters, 2004).  In Buddhism, it is immoral to use stem cells obtained from cloned 
embryos (Keown, 2004).  
 When discussing therapeutic cloning, the ethics behind donating the eggs to perform 
research has to be discussed. Stem cell researchers need eggs to perform SCNT, with the goal of 
producing stem cells that match patients’ DNA (Pearson, 2006).  So far, scientists have relied on 
women undergoing fertility treatment to obtain their extra eggs after the women’s agreement for 
surplus egg donation.  Unfortunately, researchers are facing some difficulty in obtaining eggs. To 
increase availability of human eggs, several labs have persuaded some women by offering them 
financial rewards.  This leads to a debate about how such women should be compensated 
(Pearson, 2006). Some argue that women have to be compensated for the distress and effort 
involved in the process.  Others are concerned that this will trigger poor women to give up their 
eggs for money (Pearson, 2006).  Is this process mostly for “therapeutic” or “commercial” 
purposes? 
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Parthenotes Ethics  
 
As mentioned in Chapter-1, parthenogenesis is defined as the process by which a single 
egg can develop in the absence of a male counterpart (Brevini and Gandolfi, 2008). In nature, 
this process of asexual reproduction is commonly used to create worker bees and ants.  In 
primates and humans, an unfertilized egg is treated with chemicals such as strontium chloride to 
induce cell division.  The embryo can divide to the blastocyst stage from which ES cells are 
obtained, but the embryo cannot produce a child.  When dealing with the ethics of 
parthenogenesis, we have to ask ourselves:  Are we dealing with a human being? Are they 
"lesser humans," "diseased humans," or "not humans at all" (Jones, 2003)? 
Not much has been written by Catholic bioethicists on the specific question of the parthenote 
personhood (Latkovic, 2006).  Parthenote advocates propose that destruction of a parthenote 
embryo raises fewer ethical problems, because the created embryos are unable to complete 
gestation, hence such an embryo is considered non human.  Dr. William Cheshire retorts that 
"careful examination of all the medical evidence, however, fails to demonstrate conclusively that 
the living human parthenote embryo can not be a human being," therefore, designating a 
parthenote as “ambiguous humanity” is premature (Family Research Council, 2008).   
 Unlike the clearly negative Catholic stance on therapeutic cloning and using surplus IVF 
embryos, the Catholic stance on parthenogenesis is not clear, but it has accepted a “wait-and-see” 
approach, says Tadeusz Pacholczyk, a neurologist and priest at the National Catholic Bioethics 
Center in Philadelphia (Barry, 2007). Therefore, the Catholic Church will not have an official 
conclusion until the scientific research establishes whether blastocyst parthenotes are non-viable 
balls of cells or viable human embryos that happened to be defective.  Pacholczyk states:  "Until 
we have really clear and convincing evidence whether [of what] makes a true human embryo, the 
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church is not going to step into these parthenogenesis waters” (Jones, 2003).  In general 
however, the Catholic Church sees parthenogenesis contrary to moral law because it contradicts 
the dignity of human procreation and conjugal union (Statement of the Catholic Leadership 
Conference on Human Cloning, 2001).  So in summary, the religious stance on parthenotes can 
be divided to two groups: A) Those who argue that the parthenote is not a viable true embryo 
since it can never develop, and B) those who hold that a parthenote embryo should be treated like 
a normal embryo unless it can be proven otherwise (McConchie, 2005). 
 
Embryonic Germ Cells Ethics  
 When discussing the ethics of embryonic germ cells (EGCs), the topic of abortion is 
correlated since EGCs are derived from aborted fetuses not 5-day old embryos (Embryonic Germ 
Cells, 2007).  In Judaism, abortion is permitted only if there is a direct danger to the life of the 
mother carrying the fetus, while abortion to prevent abnormalities in a fetus is forbidden 
(Eisenberg, 2006).  Although abortion in Judaism is a severe offense, it is hard to justify the use 
of tissues from EGCs to save lives fearing from encouraging abortion.  This is a case where the 
charge of preventative endorsement could be the avoidable death of human beings (Eisenberg, 
2006).  In Islam, abortion is allowed if performed before the fourth month of pregnancy 
(Weckerly, 2006). Muslim jurists have made a distinction between the early stages of pregnancy 
and its later stages. For example, if a woman was attacked by someone and aborts her baby in the 
early pregnancy, that person’s penalty will be less than if he attacked a pregnant woman during 
her full pregnancy (Siddiqi, 2002).  
For many Hindus, abortion is a terrible act (Castillo, 2006), however there are some 
exceptions when saving the life of the mother (Castillo, 2006).  EGCs as mentioned are obtained 
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from aborted fetuses, so the question that rises is: Where does this generally negative position on 
abortion leave Hindus on the subject of EGC stem cell research?  Dr. Valavandan Manickavel of 
www.hinduismtoday.com states that this is one of the major ethical questions for Hindus.  
Hindus follow other the religions in supporting the saving of lives, but how far people should go 
to save lives it is difficult to judge and define (Castillo, 2006).  The Singapore Hindu 
Endowment Board in their written response on this issue for the Singapore Bioethics Advisory 
Committee recently offered a typically ambiguous statement: "There is no non-acceptance to the 
use of these [EGCs] to protect human life, and to advance life by curing disease."  Later they 
added: "Killing a fetus is a sinful act" (Manickavel, 2004).  Although there is no Hindu rejection 
of EGCs themselves (Walters, 2004), the Hindu Endowments Board of Singapore went on to 
designate its rejection of EGCs research because the rest of the fetus would be killed (Walters, 
2004). 
In Buddhism, some believe EGCs are permissible because the main fetal donor is already 
deceased. The case might be similar to cadaveric organ donation for transplantation (Keown, 
2004).  The Catholic Church allows the use of germ cells if they came from non-deliberate 
miscarriages (Pacholczyk, 2008). 
Induced Pluripotent Stem Cells Ethics  
 As was indicated in chapter-1, upon the insertion of four genes into a human skin 
fibroblast cell, these genes are able to re-program or induce the cell into ES-like cells (iESCs) 
(Humphrey, 2008).   Some scientists claim iES cells have the same potential as ESCs that can be 
grown and differentiated into any kind of human tissues to cure different diseases (Humphrey, 
2008).  Recently two research teams successfully reprogrammed human skin cell to behave like 
ESCs.  This finding was welcomed by Catholic leaders as being a moral landmark with widely 
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enormous clinical promise.  Dr. Marie Hilliard, RN, director of bioethics and public policy for 
the National Catholic Bioethics Center in Philadelphia said, "From both a practical and moral 
perspective, this advance represents a significant benefit over embryonic stem cell research" 
(Doyle, 2007).  However only time will tell whether iESCs truly have the same full medical 
capabilities as ESCs. 
Adult Stem Cells Ethics  
Adult stem cells (ASCs) are considered to be the most ethically reasonable source of 
obtaining stem cells.  ASCs such as hematopoietic stem cells (HSCs) have been used for over 35 
years, saving hundreds of lives.  ASCs as opposed to ESCs pose far fewer ethical problems for 
any major world religion since no embryos destruction is involved (Shannon, 2006).  Marvelous 
discoveries continue to show that ASCs carry many of the benefits of ESCs but without the 
negative ethics of embryo destruction (Shannon, 2006). So far, the five major religions of the 
world do not present any objections towards ASCs. Pope Benedict XVI approved ASCs research 
(Catholic Online, 2008). As stated by Jakki Jeffs of Alliance for Life Ontario: 2001-JUL: "Adult 
stem cell research provides a legitimate, moral and ethical alternative area of research. Adult 
stem cell research has already been used successfully for therapeutic benefit in human beings" 
(Robinson, 2007). 
 
Chapter-3 Conclusion 
 In this chapter (3), the stances on ESCs were viewed based on the five major religions in 
the world. The negative Catholic Christian view on human ESCs is contrasted with the positive 
view of Judaism and Islam.  In Christianity, the embryo is a human being at conception, whereas 
in Judaism 40 days after conception, and in Islam after 120 days.  Based on how each religion 
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answers the question of when life begins, its stance on ESCs was determined, although the 
Hinduism stance on ESCs is inexact.  All five major religions permit and support the use of 
ASCs.  Surplus embryos taken from IVF clinics are permitted to be used for research in Islam, 
Hinduism, and Judaism, as opposed to Christianity (though not by all groups) and Buddhism.  
Islam, Judaism, and Hinduism (most likely) support therapeutic cloning, contrasted with 
Christians and Buddhism. The use of EGCs from aborted fetuses was allowed under certain 
circumstances by each religion as discussed above, especially if the fetus is already dead.  Since 
parthenogenesis and induced pluripotent stem cells are new methods of obtaining stem cells, 
little is mentioned about them, but they do seem to provide promising sources for stem cells that 
have the same or similar properties as ESCs.  
 
Author’s Perspective (For Chapters-1 & 3) 
The author for this section of the IQP strongly supports the use of embryonic stem cells 
obtained from IVF.  These embryos would be discarded anyways, so if these embryos were used 
to derive immortal ES cell lines that can be expanded to create large numbers of cells, it would 
potentially benefit millions of people and improve the health standards and quality of nations.  
New methods of obtaining adult stem cells have to be researched, as these cells provide a 
feasible alternative to embryonic stem cells without all of the controversial ethical issues.  
Induced pluripotent stem cells are a clear indication of advanced scientific technology, and 
exemplify a worthy effort to avoid using embryos.   
As seen in Chapter-3, religious bodies and their representatives have various reactions 
towards ESCs research. The responses were based on their faith, religious text, and theological 
teachings.  Being a Muslim, it was surprising and interesting to this author to know that Islam is 
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among the most permissible religions regarding using embryonic stem cells for research 
purposes.  In fact, Islam is one the religions that has rigid traditions of legal laws. As a Muslim I 
believe in the sense of viewing the embryo as a human being through “process” or “stages” of 
development, and not from the “moment” of conception.  Though as mentioned in this chapter, 
in Islam stem cells can be obtained from an embryo before the fourth month, before ensolument 
occurs.  It seems that Islamic and Christian stances on ESCs are totally different; maybe if the 
two stances were balanced, a compromised solution would be achieved!  Sometimes, it is hard to 
judge in this complex argument because in the end we are humans, when most of the time we 
judge situations based or on our feelings and emotions before our facts and common sense.  For 
example, if my parents or any member in my family were afflicted with any debilitating disease, 
am I going to do anything to save their lives even if the cost was obtaining stem cells from 
human embryos?  As a scientist, the most important question to me is as following:  If I am given 
the chance to work with ESCs, do I still want to conduct the research, knowing morally it is 
condemned by some religions, but acknowledging the huge benefits from such research?  If 
nobody executes the research, who is going to do it?  The situation is like going to a war 
knowing for sure the cost is losing civilian-lives!  In turn, as a scientist, my obligation is to 
develop and design new ways to achieve a compromised solution of obtaining stem cells, such as 
iPS cells, which satisfy most religious groups, since as seen in this section, religion and science 
have to intersect.  This way, we will not sacrifice scientific advances for the expense of our 
moral values.  It is important to relate theology to the problems of the modern world and the new 
bio-advancements.  Also, as new technologies are evolved for the sake of mankind, (i.e. IVF to 
assist reproduction), there has to be some sort of limitation, or a red-line that has to be drawn so 
these technologies will not be misused solely for commercial purposes. The stem cell debate, 
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especially for ESCs, is very complicated and has to be taken seriously.  There should be 
published guidelines based on one-and-only-one dynamic religious-scientific organization 
considering and respecting each religion’s views and implications. 
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CHAPTER 4:  STEM CELL LEGALITIES 
 
 
Research on stem cells has become one of the most controversial topics of the 21st 
century.  Many people support stem cell research and use, while others strongly oppose it.  Stem 
cells are such a heavily debated issue that laws and regulations have been implemented to 
support, fund, or even prohibit stem cell research in various countries.  Stems cells isolated from 
human embryos stir the most commotion, and therefore have the most laws and regulations.  
Legal issues concerning stem cells have had an impact on the progress made in this particular 
field of medical research.  Due to personal beliefs and moral standings on stem cells, many 
limitations have been implemented, and have possibly restrained potential breakthroughs in 
treatments for many diseases. 
 
U.S. Federal Stem Cell Legislation 
In the United States, research involving human ES cells has slowed because of moral 
debates, political opposition, and confusion about the science.  In August 2001, President Bush 
declared that scientists who receive federal research funds, which is the most common source of 
research funding, could only work with a handful of stem cell lines that were in developed before 
August 9, 2001.  He said research on these stem cell lines was permissible because the embryo 
had already been destroyed (Kruse, 2008).  Since Bush's address, the public has debated the 
current federal policy. Supporters of stem cell research find the policy far too restrictive, while 
critics say no research of this type should take place under any circumstances, much less 
federally funded research.  
 66
The White House initially said that more than sixty usable ES cell lines were available 
for use, but after tests were performed to certify uniqueness, in reality the number was closer to 
nine, most of which are now considered outdated.  To intensify the problem, Congress has 
proposed bills that would make it illegal to use cloning to create new stem cell lines for 
biomedical research.  The process of cloning would be required to create ES cell lines specific to 
a given patient that would be less likely to be rejected.  The possibility that Congress might 
outlaw the use of cloning technology to derive new cell lines is discouraging researchers.  Even 
if the Senate passed a pro-research bill, the House of Representatives would be unlikely to agree.  
And even if such a bill made it through Congress, President Bush would likely veto it, since he 
strongly opposes most stem cell research.   
In June of 2004, 58 U.S. Senators sent a letter to President Bush urging him to change his 
policy and expand the number of stem cell lines eligible for federally funded research.  
Surprisingly among the signatories were abortion opponents Trent Lott and Orrin Hatch.  In 
April of 2004, 206 members of the U.S. House of Representatives signed a similar letter to try to 
persuade the President.  To date the President has not changed his opinion about research on 
human embryonic stem cells (Kruse, 2008). 
 
U.S. States and Stem Cells 
 Individual states have the authority to pass laws to permit human embryonic stem cell 
research using state funds.  Unless Congress passes a law that bans it, states may pay for research 
using human embryonic stem cell lines that are not eligible for federal funding (Palca, 2007).  
However not all states agree on this issue either.  State laws may restrict the use of ES cells from 
some or all sources, or specifically permit certain activities.  While some states have passed 
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legislations that ban all forms of cloning or human ES cell research, others strongly support 
research and provide significant funding (Stem Cell Research, 2008). 
In 2002, California became the first state to officially endorse human ES cell research, 
including experiments that involve cloned embryos.  In 2004, New Jersey established the nation's 
first state-supported stem cell research facility.  Later in 2004, California voters approved 
Proposition 71, a bond measure that will provide three billion dollars over ten years to aid stem 
cell research, including work with cloned human embryos and the stem cells they produce.  Stem 
cell research policies in California, Connecticut, Illinois, Iowa, Maryland, Massachusetts, New 
Jersey, and New York, encourage ES cell research, while other states like South Dakota strictly 
prohibits research on embryos regardless of the source. States that permit and fund ES cell 
research have specific guidelines for researchers, such as consent requirements, and approval and 
review processes for projects (Dunn, 2005). 
 Thus, due to the strict federal stance on funding ES cell research, state governments have 
taken the unusual step of funding biomedical research, which is typically done with federal 
grants.  Stem cell scientists in favorable states are pursuing private and state bond avenues of 
support, however there could be complications if scientists in different states want to collaborate.  
Embryonic stem cells have come to represent potential treatments for many people suffering 
from incurable diseases.  "This is why we are not waiting for anyone to do it for us," California 
Governor Arnold Schwarzenegger has said. "We are creating the action right here in California."  
California is leading the way by passing a bill that provides three hundred million dollars a year 
for stem-cell research.  But California isn't alone in its support of embryonic stem cells. 
Connecticut Governor Jodi Rell said the goal of her state's ten million dollar annual funding was 
to find stem cell therapies for a wide range of diseases (Palca, 2007). 
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“Some states current standing on the issue of stem cells are described below: 
• In November 2004 voters in California passed of Proposition 71 to fund adult and 
embryonic stem cell research. The measure authorized the issuance of bonds in the 
amount of $3 billion beginning in 2005 not to exceed sale of over $350 million per year.  
Training grants have been awarded, but the award of research grants has been slowed by 
litigation. As a result, the Governor decided to loan the institute $150 million in August 
2006, and the institute is currently seeking proposals. The California Institute of 
Regenerative Medicine (CIRM), which administers the state stem cell research program, 
has developed a Scientific Strategic Plan approved by its governing board in December 
2006. The plan projects that CIRM will spend over $622 million through FY 2008-09.  
 
• In 2005 the Connecticut legislature passed Senate Bill 934, which created a fund to 
provide ten million dollars in grants a year over ten years to do the same. Applications for 
the first round of grant awards were due in July 2006.  
 
• Illinois Governor Blagojevich signed an executive order to create the Illinois 
Regenerative Medicine Institute (IRMI) and provide for grants to medical research 
facilities for adult and embryonic stem cell research. At the same time, the Governor 
transferred $10 million to this new program, and grants were awarded in April 2006. In 
August 2006 an additional $5 million in FY 07 funds appropriated to the health 
department was allocated to the stem cell program and grants were awarded.  The Illinois 
legislature passed a bill in August 2007 permitting IRMI to conduct stem cell research on 
cells from any source.  
 
• Indiana legislators created an adult stem cell research center at Indiana University. 
$50,000 dollars has been appropriated to establish the center.   
 
• In 2006 the Maryland legislature created the Maryland Stem Cell Research Fund, which 
will provide grants for adult and embryonic stem cell research.  Unused donated materials 
under this program may not include oocytes.  The Maryland budget for FY 2007 included 
$15 million for the fund.  
 
• After overriding the Governor's veto, Massachusetts legislators added two new sections 
to the statutes on stem cell research.  The first creates an institute for stem cell research 
and regenerative medicine at the University of Massachusetts with an appropriation of 
$1,000,000 to be spent on the stem cell biology core.  The second establishes a life 
sciences center to promote life sciences research in advanced and applied sciences, 
including but not limited to stem cell research, regenerative medicine, biotechnology, and 
nanotechnology and creates the Life Sciences Investment Fund to make appropriations, 
allocations, grants or loans to leverage development and investments in stem cell research 
and other areas. $10,000,000 was appropriated to the fund.   
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• In early 2004 New Jersey became the first state to appropriate funds specifically for adult 
and embryonic stem cell research. State funding for adult stem cell research was already 
occurring in at least one state, Ohio. In FY05 and FY 06 a total of $23 million in general 
revenues were allocated to the New Jersey Stem Cell Institute, according to New Jersey's 
Commission on Science and Technology. The state of New Jersey awarded its first grants 
in December 2005. Grants were awarded to 17 institutions for research on stem cells 
from embryos and other sources. In 2007, voters rejected a ballot measure to allow the 
sale of bonds to fund stem cell research.  
 
• In 2007 New York legislators created The Empire State Stem Cell Trust to support stem 
cell research on cells from any source. $100 million was earmarked for FY2007-2008, 
and $500 million was earmarked at $50 million per year for ten years beginning in FY 
2008-2009. Applications for the first grant awards are due January 4, 2008.  
 
• The Center for Stem Cell and Regenerative Medicine was established in 2003 with $19.4 
million in state funding to support research on adult stem cells. The center also received 
$8 million from the state in 2006.  
 
• The Washington legislature created the Life Sciences Discovery Fund, which may result 
in grants for stem cell research in the future. Planning for the fund is still in process.  
 
• On October 10, 2006 the Wisconsin Governor announced $100 million funding for Stem 
Cell Products, Inc., which creates blood products from embryonic stem cells.   
 
• The Virginia legislature has created a fund to support adult stem cell research only. 
Money was not appropriated at the time the fund was established.  
 
• Nebraska statutes limit the use of state funds for embryonic stem cell research. 
Restrictions only apply to state healthcare cash funds provided by tobacco settlement 
dollars. 
 
• Arizona law prohibits the use of public monies for reproductive or therapeutic cloning.“ 
(Eligibility Criteria, 2008) 
 
 
The Current Situation in the U.S. 
 Arguments are currently being made for removing the Bush restrictions.  The President's 
policy limits federal funding to research to only about twenty cell lines that existed over three 
years ago.  Scientists argue that dozens of other stem cell lines have since been created through 
private funds, some of which are easier to access, easier to maintain in the lab, easier to turn into 
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desired cell types, and more likely to contribute to actual human cell therapies (Ford, 2006).  
Since the new ES lines have not been in contact with mouse co-feeder cells, unlike all of the 
approved lines, the cells can be used for many new procedures.  In February 2005 a poll taken by 
Results for America, a project of the Civil Society Institute, demonstrated that 70 percent of 
Americans favored loosening the Bush restrictions on stem cell funding.  Those in favor included 
more than half of conservatives (56 percent), 80 percent of moderates, and 84 percent of liberals.  
However, not everyone agrees that there should be more federal funding for stem cell research.  
Especially those who, like President Bush, believe life begins with the very early human embryo 
(Dunn, 2005). 
 The U.S. is still considered a leader in stem cell research, but there is concern that it is 
slipping behind countries such as the U.K., Korea, Singapore, Sweden, Israel, Australia and 
China.   Private funding for stem cell research in the U.S. currently provides more funding than 
the federal Government, which bans funding for research on new ES cells (Agnew, 2003).  This 
restrictive U.S. policy makes collaboration with foreign scientists more difficult, and leads to a 
large amount of worldwide funding for stem cell research on less useful lines.   
 
International Stem Cell Policies 
In the U.K., studies in ES cell research are subject to the oversight of the Human 
Fertilization and Embryology Authority (Moreno, 2006). Clinical studies in adult stem research 
are subject to review from an independent body as well.  In Canada, the largest source of stem 
cell research funding is the Canadian Institutes of Health, followed by government and health 
charities (Cook, 2004).  As restrictions have tightened, the US has seen more scientists move to 
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the UK, which allows research on ES cells derived from human embryos up to 14 days of 
development.   
Governments around the world are closing the gap, and a number of countries are 
emerging as powerhouses in the field.  In Australia, the government is funding research and 
helping to set up a national stem cell research center. In the Czech Republic, Dvorak's lab at the 
Mendel University of Agriculture and Forestry is part of a Centre for Cell Therapy and Tissue 
Repair, and is supported and fully funded by the government.  South Korea has derived almost as 
many new ES lines as the United States, according to the Globe survey, and researchers there 
were the first to claim to create stem cells from a cloned human embryo, a scientific milestone 
that American researchers initially grumbled should have happened in the United States (Ebbin, 
2007), although this initial South Korean claim has since been withdrawn for data fabrication. 
 
Future Stem Cell Policies in the U.S. 
 Despite the current restrictive policies on stem cell research under President Bush, drastic 
changes could be implemented in the near future with a presidential election in 2008.  Depending 
on who wins, the federal laws restricting research funds could be lifted.  The two leading 
candidates have very different positions on the subject and whoever is elected will have a large 
impact on advancements made in stem cell research.  Barack Obama supports all stem cell 
research, while John McCain opposes human embryonic research.  Their official positions on the 
matter are: 
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Barack Obama 
 “I stand in full support of the Stem Cell Research Enhancement Act as I did when this 
bill was introduced and sent to the President’s desk in the 109th Congress.  I am proud to be an 
original cosponsor of this bill.  I am frustrated by the opposition this bill has generated, and 
saddened that we are preventing the advancement of important science that could potentially 
impact millions of suffering Americans. The study of stem cells holds enormous promise for the 
treatment of debilitating and life-threatening diseases. However, in order to reach this level of 
medical achievement, much more research is necessary to understand, and eventually harness, 
the amazing potential of stem cells. Instead of creating roadblocks, we must all work together to 
expand federal funding of stem cell research and continue moving forward in our fight against 
disease by advancing our knowledge through science and medicine.  Two of my constituents, 
Mary Schneider and her son Ryan, are well aware of the potential of cord blood treatments. Her 
son, diagnosed with cerebral palsy at 2 years of age, has made what appears to be a full recovery 
after treatment with his own cord blood. Despite the compelling results witnessed by the 
Schneider family, they also firmly believe and support expanded research of embryonic stem 
cells to combat disease.  The President’s veto of the stem cell bill proposed in the last Congress 
prevents government funding beyond 78 previously established stem cell lines. However, recent 
estimates on the number of viable cell lines bring the numbers down closer to 20. Clearly, we are 
moving backwards in our efforts with these current restrictions. Stymieing embryonic stem cell 
research is a step in the wrong direction. It closes the door on many Americans awaiting new 
treatments that could potentially provide a better quality of life, or, perhaps, even save their life.  
My hope, and the hope of so many in this country, is to provide our researchers with the means 
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to explore the uses of embryonic stem cells so that we can begin to turn the tide on the 
devastating diseases affecting our nation and the world” (LaBolt, 2007). 
 
John McCain 
 “Stem cell research offers tremendous hope for those suffering from a variety of deadly 
diseases - hope for both cures and life-extending treatments. However, the compassion to relieve 
suffering and to cure deadly disease cannot erode moral and ethical principles.  For this reason, 
John McCain opposes the intentional creation of human embryos for research purposes. To that 
end, Senator McCain voted to ban the practice of "fetal farming," making it a federal crime for 
researchers to use cells or fetal tissue from an embryo created for research purposes. 
Furthermore, he voted to ban attempts to use or obtain human cells gestated in animals. Finally, 
John McCain strongly opposes human cloning, and voted to ban the practice, and any related 
experimentation, under federal law.  As President, John McCain will strongly support funding 
for promising research programs, including amniotic fluid and adult stem cell research and other 
types of scientific study that do not involve the use of human embryos.  Where federal funds are 
used for stem cell research, Senator McCain believes clear lines should be drawn that reflect a 
refusal to sacrifice moral values and ethical principles for the sake of scientific progress, and that 
any such research should be subject to strict federal guidelines” (Addressing. 2008). 
  
 Due to the moral debate on stem cells, especially human embryonic stem cells, many 
laws and regulations have been placed on the use of these cells.  Positions on stem cells range 
from supporting and promoting research through alternative funding to completely prohibiting 
any use of particular lines of stem cells.  Legalities on stem cells have directly effected the 
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advancements in this field, and have limited the potential of developing new procedures for 
many diseases.  Even though our federal government does not support stem cell research at this 
time, many other sources of funding have supported research and other countries continue to 
make breakthroughs.  Stem cells hold great potential in treating many diseases, but procedures 
are relatively new and more research is needed for prove them safe and effective.  Funding for 
this research is critical, but is not easily obtained.  The legal issues on stem cells greatly impact 
the level of advancement and will continue to restrict new discoveries as long as there are 
limitations on research.  
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CONCLUSIONS 
 
 
 
The author for Chapters 1 and 3 of this IQP strongly supports the use of excess embryos 
obtained for the purpose of reproduction via IVF to derive new ES cell lines.  This author also 
supports all efforts to develop new methods for obtaining alternative sources of ESCs such as 
ASCs and iPS cells.  The results of such alternative methods would be an excellent compromise 
solution for using ES cells without destroying an embryo that should satisfy most religious 
groups. The author believes in viewing the embryo as a human being through various “stages” of 
development, not from the “moment” of conception where no ensolument has occurred yet, 
hence using embryos to derive ESCs within 5-6 days to obtain the blastocyst is acceptable. The 
author also feels the current federal stance against ES cells is too strict, and believes the US 
Federal government must fund and encourage research on ESCs because of the enormous 
potential that these cells have in curing afflicted people with debilitating diseases. At the same 
time the author also agrees with individual states that have taken the initiative to privately fund 
ESCs research.  
The author for chapters 2 and 4 believes that all types of stem cells should be utilized in 
research and medical procedures.  This author disagrees with current US federal laws that do not 
allow national government funding to derive new ES cell lines, and believes more could be done 
and should be done by the government to support the use of stem cells.   
 
